研究者詳細

顔写真

シライ　ツヨシ
白井　剛志
Tsuyoshi Shirai
所属
病院　内科　リウマチ膠原病内科
職名
講師
学位

  • 医学博士 （東北大学）

経歴 8

  • 2024年1月 ～ 継続中
    東北大学病院　リウマチ膠原病内科　講師

  • 2019年10月 ～ 2023年12月
    東北大学病院　リウマチ膠原病内科　院内講師

  • 2016年4月 ～ 2019年9月
    東北大学大学院医学系研究科　血液免疫病学分野　助教

  • 2013年7月 ～ 2016年3月
    Stanford University　Immunology & Rheumatology　Post doctoral fellow

  • 2013年2月 ～ 2013年6月
    東北大学メディカルメガバンク機構　助教

  • 2012年10月 ～ 2013年1月
    公立志津川病院

  • 2012年4月 ～ 2012年9月
    東北大学病院

  • 2005年4月 ～ 2008年3月
    日鋼記念病院

︎全件表示 ︎最初の5件までを表示

学歴 2

  • 東北大学大学院　医学系研究科　血液免疫病学分野

    2008年4月 ～ 2012年3月

  • 東北大学　医学部

    1999年4月 ～ 2005年3月

研究キーワード 8

  • 抗MDA5抗体陽性皮膚筋炎

  • 腸内細菌叢

  • 潰瘍性大腸炎

  • PKM2

  • 細胞内代謝

  • 自己抗体

  • 高安動脈炎

  • 血管炎

研究分野 2

  • ライフサイエンス / 消化器内科学 /

  • ライフサイエンス / 膠原病、アレルギー内科学 /

受賞 18

  1. Modern Rheumatolology Top Reviewer Award

    2026年3月　日本リウマチ学会

  2. 医学部奨学賞 金賞

    2025年1月　東北大学

  3. 医学奨励賞

    2025年1月　宮城県医師会

  4. 内科学会ことはじめ指導教官賞 2受賞

    2024年4月　日本内科学会

  5. 治験実施若手奨励者賞

    2023年11月　東北大学病院

  6. Modern Rheumatology Top Reviewer Award

    2023年4月　日本リウマチ学会

  7. 治験実施優良者賞

    2022年11月　東北大学病院

  8. 医学研究奨励賞

    2022年11月　日本医師会

  9. 内科学会ことはじめ 指導教官賞

    2022年4月　日本内科学会

  10. 2020年度若手共同研究奨励研究費

    2020年7月　東北大学大学院医学系研究科

  11. E-bursary award

    2020年6月　ヨーロッパリウマチ学会

  12. 内科学会ことはじめ 指導教官賞

    2019年4月　日本内科学会

  13. 難病財団医学研究助成金

    2018年1月　難病財団

  14. 東北医学会奨学賞A

    2017年1月　東北大学

  15. かなえ医薬振興財団助成金

    2016年11月

  16. 三浦記念リウマチ学術研究賞

    2013年5月　リウマチ財団

  17. 国際ワークショップ賞

    2011年7月　日本リウマチ学会

  18. 第4回リトリート最優秀演題賞

    2011年1月　東北大学

︎全件表示 ︎最初の5件までを表示

論文 155

  1. Common dysbiosis features between patients of different social environments in Takayasu arteritis: comment on the article by Fan et al 国際誌

    Tsuyoshi Shirai, Satoshi Watanabe, Natsuko O. Shinozaki, Kairi Baba, Hiroyuki Yamasaki, Tomonori Ishii, Hiroshi Fujii

    Arthritis & Rheumatology　75　(7)　1291-1292　2023年7月

    DOI： 10.1002/art.42438 　

  2. Novel Diagnostic Autoantibodies Against Endothelial Protein C Receptor in Patients With Ulcerative Colitis. 国際誌

    Yoichi Kakuta, Tsuyoshi Shirai, Dermot P B McGovern, Jonathan Braun, Hiroshi Fujii, Atsushi Masamune

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association　21　(3)　844-846　2021年12月28日

    DOI： 10.1016/j.cgh.2021.12.035 　

    詳細を見る 詳細を閉じる

    There have been many reports on serologic autoantibodies in inflammatory bowel diseases (IBD),1 consisting of ulcerative colitis (UC) and Crohn's disease (CD), and recently Kuwada et al2 reported a new autoantibody against integrin αvβ6 with high sensitivity and specificity for UC. Concurrently, we had discovered autoantibodies against endothelial protein C receptor (EPCR) in Takayasu arteritis (TAK), which is sometimes complicated by UC.3 Interestingly, this autoantibody was found in most patients with TAK associated with UC, and we found that the positivity rate in patients with UC without TAK was also high, suggesting that anti-EPCR antibody is a candidate autoantibody useful for the diagnosis of UC.4 To clarify the diagnostic usefulness of anti-EPCR antibodies in patients with IBD and their relationship to several disease subphenotypes and their disease activities, we analyzed the serum samples from patients with IBD and non-IBD control subjects in Japan and the United States.

  3. Distinct autoantibodies against endothelial protein C receptor in ulcerative colitis. 国際誌

    Tsuyoshi Shirai, Yoichi Kakuta, Hiroshi Fujii

    Gastroenterology　161　(5)　1724-1725　2021年3月24日

    DOI： 10.1053/j.gastro.2021.03.037 　

  4. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis 査読有り

    Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori Ishii, Yuko Shirota, Fumiyoshi Fujishima, Fumiaki Takahashi, Yoichi Kakuta, Yoshitake Kanazawa, Atsushi Masamune, Yoshikatsu Saiki, Hideo Harigae, Hiroshi Fujii

    Nature Communications　2020年12月

    DOI： 10.1038/s41467-020-15088-0 　

  5. Insufficient Use of Corticosteroids Results in Higher Relapse in Takayasu Arteritis

    Tomoyuki Muto, Tsuyoshi Shirai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　70　2018年9月

    ISSN：2326-5191

    eISSN：2326-5205

  6. Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity 査読有り

    Ryu Watanabe, Tsuyoshi Shirai, Hong Namkoong, Hui Zhang, Gerald J. Berry, Barbara B. Wallis, Benedikt Schaefgen, David G. Harrison, Jennifer A. Tremmel, John C. Giacomini, Jorg J. Goronzy, Cornelia M. Weyand

    JOURNAL OF CLINICAL INVESTIGATION　127　(7)　2725-2738　2017年6月

    DOI： 10.1172/JCI92167 　

    ISSN：0021-9738

    eISSN：1558-8238

  7. NADPH oxidase deficiency underlies dysfunction of aged CD8(+) Tregs 査読有り

    Zhenke Wen, Yasuhiro Shimojima, Tsuyoshi Shirai, Yinyin Li, Jihang Ju, Zhen Yang, Lu Tian, Jorg J. Goronzy, Cornelia M. Weyand

    JOURNAL OF CLINICAL INVESTIGATION　126　(5)　1953-1967　2016年5月

    DOI： 10.1172/JCI84181 　

    ISSN：0021-9738

    eISSN：1558-8238

  8. The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease 査読有り

    Tsuyoshi Shirai, Rafal R. Nazarewicz, Barbara B. Wallis, Rolando E. Yanes, Ryu Watanabe, Marc Hilhorst, Lu Tian, David G. Harrison, John C. Giacomini, Themistocles L. Assimes, Jrg J. Goronzy, Cornelia M. Weyand

    JOURNAL OF EXPERIMENTAL MEDICINE　213　(3)　337-354　2016年3月

    DOI： 10.1084/jem.20150900 　

    ISSN：0022-1007

    eISSN：1540-9538

  9. A novel autoantibody against ephrin type B receptor 2 in acute necrotizing encephalopathy 査読有り

    Tsuyoshi Shirai, Hiroshi Fujii, Masao Ono, Ryu Watanabe, Yuko Shirota, Shinichiro Saito, Tomonori Ishii, Masato Nose, Hideo Harigae

    JOURNAL OF NEUROINFLAMMATION　10　2013年10月

    DOI： 10.1186/1742-2094-10-128 　

    ISSN：1742-2094

  10. An innovative method to identify autoantigens expressed on the endothelial cell surface: serological identification system for autoantigens using a retroviral vector and flow cytometry (SARF). 国際誌 査読有り

    Tsuyoshi Shirai, Hiroshi Fujii, Masao Ono, Ryu Watanabe, Tomonori Ishii, Hideo Harigae

    Clinical & developmental immunology　2013　453058-453058　2013年

    DOI： 10.1155/2013/453058 　

  11. A novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus 査読有り

    Tsuyoshi Shirai, Hiroshi Fujii, Masao Ono, Kyohei Nakamura, Ryu Watanabe, Yumi Tajima, Naruhiko Takasawa, Tomonori Ishii, Hideo Harigae

    ARTHRITIS RESEARCH & THERAPY　14　(4)　2012年

    DOI： 10.1186/ar3897 　

    ISSN：1478-6354

  12. Successful treatment of systemic lupus erythematosus-related severe aseptic meningitis following a switch to dexamethasone: a case-based review

    Hiroko Sato, Tokio Katakura, Yuito Tanno, Sou Itoi, Tomoaki Machiyama, Yosuke Hoshi, Yusho Ishii, Tsuyoshi Shirai, Hiroshi Fujii

    Clinical Rheumatology　2026年9月25日

    DOI： 10.1007/s10067-026-08440-0 　

  13. JCS 2026 Guideline on Management of Large Vessel Vasculitis.

    Yoshikazu Nakaoka, Yoshiko Watanabe, Takahiko Sugihara, Kenji Nagasaka, Naoto Tamura, Hajime Yoshifuji, Nobuyuki Yajima, Fumika Aono, Takuya Hashimoto, Akihiro Ishizu, Tomohiro Iida, Tomonori Ishii, Takatoyo Kiko, Yasuhiro Maejima, Takako Miyamae, Yu Nakano, Toshihiro Nanki, Hiroaki Niiro, Hideki Ota, Noriko Okochi, Kenei Sada, Kunihiro Shigematsu, Haruhito A Uchida, Yoshiyuki Abe, Chizuko Aoki-Kamiya, Yoh Arita, Takaya Handa, Ryosuke Hiwa, Manabu Honda, Ryuhei Ishihara, Jun Ishizaki, Shuichi Ito, Toru Iwahashi, Naomi Iwata, Keiichiro Kadoba, Yuji Kamiyama, Mai Kawazoe, Takashi Kida, Genki Kidoguchi, Daisuke Kobayashi, Kazuhiro Kobayashi, Atsushi Kurata, Yoshia Miyawaki, Shun Nakagama, Norihiro Nishioka, Mitsuho Onimaru, Yasuhiro Onishi, Ryota Sakai, Ryoko Sakai, Hajime Sanada, Yuuki Shimizu, Tsuyoshi Shirai, Eri Sugano, Kei Takahashi, Shin-Ya Tamechika, Jin Ueda, Natsuka Umezawa, Ryu Watanabe, Ryo Yanai, Tsuneyasu Yoshida, Koichi Amano, Masayoshi Harigai, Mitsuaki Isobe, Hiroaki Kitaoka, Kazuo Tanemoto

    Circulation journal : official journal of the Japanese Circulation Society　2026年3月20日

    DOI： 10.1253/circj.CJ-25-0969 　

    詳細を見る 詳細を閉じる

    BACKGROUND: To provide evidence from randomized controlled trials (RCTs) for large-vessel vasculitis (LVV), including Takayasu arteritis (TAK) and giant cell arteritis (GCA), to inform the forthcoming 2026 Japanese Circulation Society (JCS) clinical practice guideline. METHODS AND RESULTS: We drafted 4 and 7 clinical questions for TAK and GCA, respectively. A systematic review (SR) of RCTs was conducted using PubMed, CENTRAL, EMBASE, and the Japan Medical Abstracts Society through March 2024. Assessed with the GRADE approach, the certainty of evidence was very low for the most critical outcomes, low for some outcomes, and moderate for only 1 outcome. Evidence for TAK was limited. Tocilizumab (TCZ) resulted in a numerically lower relapse rate vs. placebo (risk ratio (RR) 0.73, 95% confidence interval (CI) 0.39-1.37) and was similar to adalimumab. No clear difference between mycophenolate mofetil (MMF) and methotrexate (MTX), or between abatacept (ABA) and placebo was observed. In GCA, TCZ reduced relapse (RR 0.29, 95% CI 0.09-0.98) and increased remission (RR 3.56, 95% CI 2.29-5.54) over placebo at 52 weeks. Tumor necrosis factor inhibitor, ABA, and MTX showed no benefit in cranial GCA. Serious adverse events were comparable between treatment groups. Geographic variation and differences in entry criteria were noted. CONCLUSIONS: This SR was comprehensive synthesis of evidence from RCTs for LVV therapies to support the 2026 JCS guideline.

  14. Predictors of glucocorticoid-free clinical remission in patients with newly diagnosed microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study using a nationwide registry in Japan (J-CANVAS). 国際誌

    Yusuke Ushio, Risa Wakiya, Hiromi Shimada, Koichi Sugihara, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Makoto Wada, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Hirosuke Takagi, Koji Endo, Shintaro Hirata, Naoto Azuma, Tohru Takeuchi, Shoichi Fukui, Kazuro Kamada, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Tsuyoshi Shirai, Takafumi Ito, Isao Matsumoto, Toshihiko Takada, Toshiko Ito-Ihara, Takashi Kida, Nobuyuki Yajima, Takashi Kawaguchi, Yutaka Kawahito, Hiroaki Dobashi

    Arthritis research & therapy　2026年3月10日

    DOI： 10.1186/s13075-026-03780-3 　

  15. Real-world effectiveness of rituximab or intravenous cyclophosphamide versus non-use in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective cohort study of J-CANVAS. 国際誌

    Satoshi Omura, Takashi Kida, Junya Kitai, Takuya Yanagida, Daiki Nakagomi, Yoshiyuki Abe, Makoto Wada, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Hirosuke Takagi, Koji Endo, Shintaro Hirata, Naoto Azuma, Tohru Takeuchi, Shoichi Fukui, Kazuro Kamada, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Tsuyoshi Shirai, Hiroaki Dobashi, Takafumi Ito, Isao Matsumoto, Toshihiko Takada, Toshiko Ito-Ihara, Nobuyuki Yajima, Takashi Kawaguchi, Takahiro Seno, Yutaka Kawahito

    Modern rheumatology　36　(2)　261-271　2026年3月5日

    DOI： 10.1093/mr/roaf090 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: To evaluate the real-world effectiveness of rituximab (RTX) and intravenous cyclophosphamide (IVCY) compared to non-use for remission induction in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). METHODS: This observational study emulated a target trial using data from the Japan Collaborative Registry of ANCA-associated Vasculitis. Patients aged ≥20 years with newly diagnosed or relapsing MPA or GPA (2017-23) were included. RTX or IVCY use within 4 weeks defined the treatment group; others formed the control group. The primary outcome was failure to achieve remission at week 24 (Birmingham Vasculitis Activity Score = 0 and prednisolone ≤ 10 mg/day). Secondary outcomes included a composite of death, kidney failure, and relapse, and serious infection. In inverse probability weighted population, risk ratios were estimated using modified Poisson regression. RESULTS: Among 544 patients (MPA: 413, GPA: 131), 63.6% received RTX or IVCY. The risk ratio for failure to achieve remission was 0.72 (95% CI: 0.61-0.85), and for the composite outcome was 0.57 (95% CI: 0.33-0.97), and for serious infection was 1.03 (95% CI: 0.47-2.25). Results were robust in sensitivity analyses. CONCLUSIONS: RTX and IVCY improved short-term outcomes in MPA and GPA without increasing infection risk, supporting their recommendation as standard therapy.

  16. Autoantibodies and B Cells in Takayasu Arteritis and Giant Cell Arteritis: Comparative Insights into Large-Vessel Vasculitis.

    Tsuyoshi Shirai

    The Tohoku journal of experimental medicine　268　(2)　135-147　2026年3月4日

    DOI： 10.1620/tjem.2026.J008 　

    詳細を見る 詳細を閉じる

    Large-vessel vasculitis (LVV) encompasses Takayasu arteritis (TAK) and giant cell arteritis (GCA), both characterized by granulomatous inflammation of large arteries. While these diseases have distinct clinical features, the emergence of large-vessel GCA (LV-GCA) highlights an area of overlap with late-onset TAK. Although T cell- and macrophage-driven inflammation represents a shared hallmark, the contribution of B cells and autoantibodies remains less clearly defined. This review comparatively summarizes B cell mediated responses and autoantibody involvement in TAK and GCA. TAK demonstrates significant B cell activity, evidenced by B cell infiltration and the presence of tertiary lymphoid organs (TLOs) within the arterial wall. Importantly, specific autoantibodies, such as anti-endothelial protein C receptor (EPCR) and anti-scavenger receptor class B type I antibodies, have been identified. Anti-EPCR antibodies specifically associate TAK with coexisting ulcerative colitis, suggesting a shared aberrant immune pathway. In contrast, cranial GCA is primarily T cell-driven and contains relatively few B cells. However, aortic lesions in LV-GCA exhibit extensive B cell and plasma cell infiltration, including TLOs, indicating that this subtype shares key B cell mediated responses with TAK. Despite this immunological convergence, the specific autoantibody profiles appear distinct and remain incompletely characterized. Taken together, B cell and autoantibody responses are more pronounced and functionally relevant in TAK, show intermediate involvement in LV-GCA, and are least prominent in cranial GCA. These differences provide critical insights for LVV subtyping and underscore the need for further elucidation of the pathomechanisms underlying TAK, late-onset TAK, LV-GCA, and cranial GCA to enable personalized therapeutic strategies.

  17. Systematic Review and Meta-Analysis for JCS 2026 Guideline on Management of Large-Vessel Vasculitis

    Tsuyoshi Shirai, Tsuneyasu Yoshida, Eri Sugano, Ryosuke Hiwa, Ryuhei Ishihara, Ryo Yanai, Nobuyuki Yajima, Takashi Kida, Norihiro Nishioka, Ryota Sakai, Takaya Handa, Manabu Honda, Jun Ishizaki, Keiichiro Kadoba, Yuji Kamiyama, Genki Kidoguchi, Takatoyo Kiko, Daisuke Kobayashi, Kazuhiro Kobayashi, Shun Nakagama, Yu Nakano, Hajime Sanada, Shin-Ya Tamechika, Jin Ueda, Kenji Nagasaka, Takahiko Sugihara, Naoto Tamura, Yoshikazu Nakaoka

    Circ J .　2026年2月

    DOI： 10.1253/circj.CJ-25-1129. 　

  18. Association Between Bronchiectasis and Serious Infections in Microscopic Polyangiitis and Granulomatosis With Polyangiitis From the J-CANVAS. 国際誌

    Satoshi Omura, Takashi Kida, Hironori Inoue, Yuki Shimada, Daiki Nakagomi, Yoshiyuki Abe, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Hirosuke Takagi, Koji Endo, Shintaro Hirata, Naoto Azuma, Tohru Takeuchi, Shoichi Fukui, Kazuro Kamada, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Tsuyoshi Shirai, Hiroaki Dobashi, Takafumi Ito, Isao Matsumoto, Toshihiko Takada, Toshiko Ito-Ihara, Nobuyuki Yajima, Takashi Kawaguchi, Takahiro Seno, Masataka Kohno, Makoto Wada, Yutaka Kawahito

    International journal of rheumatic diseases　29　(2)　e70570　2026年2月

    DOI： 10.1111/1756-185x.70570 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Bronchiectasis is known to be more frequently observed in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) compared to the general population. However, its association with patient outcomes and the potential influence of immunosuppressive treatment on this association remain unclear. METHODS: We conducted a multicenter observational study using data from the Japan Collaborative Registry of ANCA-Associated Vasculitis (J-CANVAS). Adult patients with newly diagnosed or relapsing MPA or GPA between January 2017 and March 2023 were included. The exposure was clinically apparent bronchiectasis at baseline. Primary outcomes were serious infections and all-cause mortality; relapses were examined as a secondary outcome over 52 weeks. For each outcome, incidence rate ratios (IRRs) were estimated using multivariable Poisson regression models conditioned on confounding factors, incorporating follow-up time as an offset term. Interactions between initial treatment (prednisone dose, rituximab, cyclophosphamide, intravenous methylprednisolone, and plasma exchange) and bronchiectasis were also evaluated. RESULTS: Among 844 patients (MPA: 614; GPA: 230), 68 (8.1%) had bronchiectasis. During the follow-up period, there were 122 serious infections among 101 patients, 48 deaths, and 85 relapses among 72 patients. Adjusted IRRs for patients with bronchiectasis were 2.18 (95% CI: 1.25-3.83) for serious infections, 3.07 (1.41-6.66) for mortality, and 1.58 (0.77-3.24) for relapse. No clear interaction was detected between specific treatments and bronchiectasis. CONCLUSIONS: Bronchiectasis was associated with increased risks of serious infections and mortality in patients with MPA and GPA. However, we did not detect clear interaction by initial treatment, suggesting that avoiding specific therapies may not be necessary.

  19. Secondary Pulmonary Alveolar Proteinosis Complicated by Hemophagocytic Syndrome in a Patient with Adult-onset Still's disease: A Case-based Review.

    Tokio Katakura, Tsuyoshi Shirai, Yusho Ishii, Hiroko Sato, Yuri Yamamoto, Koji Murakami, Tsuyoshi Miura, Hiroshi Fujii

    Internal medicine (Tokyo, Japan)　65　(2)　331-336　2026年1月15日

    DOI： 10.2169/internalmedicine.5421-25 　

    詳細を見る 詳細を閉じる

    Treatment of secondary pulmonary alveolar proteinosis (SPAP) focuses on managing the underlying disease, typically myelodysplastic syndrome. However, immunosuppressive therapy may worsen the condition in autoimmune disease-associated SPAP. We report the case of a 74-year-old woman with hemophagocytic syndrome and adult-onset Still's disease, who developed ground-glass opacities and consolidations during immunosuppressive treatment. SPAP was confirmed by a biopsy and negative for anti-granulocyte-macrophage colony-stimulating factor antibodies. Although whole-lung lavage was considered if SPAP worsened significantly, no further deterioration was observed with tapering of prednisolone. A literature review and details of this case highlight the importance of attenuating immunosuppressive therapy, rather than its intensification, for SPAP in autoimmune diseases.

  20. Diabetes mellitus and cardiac disease as key predictors of rituximab-induced acute thrombocytopenia in ANCA-associated vasculitis. 国際誌

    Satoshi Akao, Masaru Shimizu, Kazushi Maruo, Hiromitsu Asashima, Yuya Kondo, Ayako Ohyama, Saori Abe, Ayako Kitada, Haruka Miki, Hiroto Tsuboi, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Makoto Wada, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Hirosuke Takagi, Koji Endo, Shintaro Hirata, Naoto Azuma, Tohru Takeuchi, Shoichi Fukui, Kazuro Kamada, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Tsuyoshi Shirai, Hiroaki Dobashi, Takafumi Ito, Toshihiko Takada, Yutaka Kawahito, Toshiko Ito-Ihara, Takashi Kida, Nobuyuki Yajima, Takashi Kawaguchi, Isao Matsumoto

    Rheumatology (Oxford, England)　65　(1)　2026年1月8日

    DOI： 10.1093/rheumatology/keaf529 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: Rituximab (RTX) is a key treatment for ANCA-associated vasculitis (AAV), but RTX-induced acute thrombocytopenia (RIAT) remains a concern. We aimed to evaluate the risk and risk factors of RIAT in patients with AAV undergoing RTX induction therapy. METHODS: Patients with new-onset microscopic polyangiitis or granulomatosis with polyangiitis who received RTX in a nationwide multicentre registry in Japan were included. RIAT was defined by platelet count reductions within 28 days post-RTX. Risk factors for RIAT were identified by using logistic regression with stepwise selection, and prediction models were developed. Model performance was assessed using C-statistics. RESULTS: Among 175 patients with AAV receiving RTX, RIAT occurred in 35.4% of them. Diabetes mellitus (odds ratio [OR] = 4.96), cardiac disease (OR = 3.57), low platelet count (OR = 1.04 per 104/μl decrease), increased serum creatinine (OR = 1.44 per 1 mg/dl increase), low albumin (OR = 2.33 per 1 g/dl decrease), and high KL-6 (OR = 1.09 per 100 U/ml increase) were identified as significant predictors. A predictive model incorporating these factors achieved a C-statistic of 0.817. CONCLUSION: RIAT is a frequent complication of RTX induction in patients with AAV, with diabetes mellitus and cardiac disease being strong risk factors. Our predictive model enables risk assessment for RIAT, allowing clinicians to optimize treatment strategies.

  21. Reversal of chronic arterial stenosis with biologic therapy including tocilizumab in Takayasu arteritis 国際誌

    Chisako Kitayama, Tsuyoshi Shirai, Tokio Katakura, Yusho Ishii, Hiroko Sato, Hiroshi Fujii

    Modern Rheumatology Case Reports　10　(1)　2026年1月6日

    DOI： 10.1093/mrcr/rxag002 　

    詳細を見る 詳細を閉じる

    Biologic agents have demonstrated efficacy in the treatment of refractory Takayasu arteritis (TAK). Although vascular stenosis is a common manifestation of the chronic phase of TAK, evidence on the effects of biologic therapy on established vascular lesions remains limited. Here, we report a case series of TAK in which chronic arterial stenosis showed marked improvement following treatment with biologic agents. The first case was a 27-year-old woman with stenosis of the left common carotid artery. Initial treatment with prednisolone (PSL) led to clinical improvement; however, the vascular lesion progressed during tapering, despite the normalisation of inflammatory markers. Reinduction with a methylprednisolone pulse and methotrexate led to slight improvement. Subsequent therapy with tocilizumab, followed by golimumab, resulted in significant and sustained improvement in the stenosis. The second case was a 20-year-old woman with wall thickening of the right brachiocephalic artery. Although PSL and methotrexate were initially administered, the progression of left subclavian artery stenosis was detected on ultrasonography before symptom onset, despite normalised inflammatory markers. The introduction of tocilizumab, with increased PSL, led to a notable improvement in the vascular lesions. These cases and a literature review suggest that biologic agents may reverse vascular remodelling in chronic TAK, even in the absence of systemic inflammatory activity. Comprehensive disease assessment using imaging modalities, alongside serum biomarkers, is essential to guide therapeutic decisions and monitor vascular changes. These findings highlight the importance of imaging-based disease monitoring and raise the potential for targeted treatment strategies aimed at both inflammation control and vascular lesion modification.

  22. Differences in Anti-αvβ6 Integrin Antibody Expression between U.S. and Japanese Cohorts in Inflammatory Bowel Disease. 国際誌

    Yoichi Kakuta, Dalin Li, Philip Debbas, Soshi Okazaki, Motoi Sawahashi, Shaohong Yang, Hideya Iwaki, Daisuke Okamoto, Hiroshi Nagai, Yusuke Shimoyama, Takeo Naito, Rintaro Moroi, Masatake Kuroha, Hisashi Shiga, Yoshitaka Kinouchi, Tsuyoshi Shirai, Hiroshi Fujii, Dermot P B McGovern, Atsushi Masamune

    Inflammatory bowel diseases　32　(1)　130-140　2026年1月1日

    DOI： 10.1093/ibd/izaf246 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Inflammatory bowel diseases (IBDs), including ulcerative colitis (UC) and Crohn's disease (CD), have complex pathologies requiring precise diagnostic tools. We evaluated the clinical utility of anti-integrin αvβ6 antibodies in diagnosing UC, focusing on differences between a U.S. cohort (self-reported White) and a Japanese cohort, and additionally assessed whether combining anti-αvβ6 with anti-EPCR improved diagnostic performance. METHODS: Serum anti-αvβ6 antibody levels were measured in 1138 participants (514 in the U.S. cohort, 624 in the Japanese cohort), including 1093 IBD cases and 45 healthy control subjects. Positivity rates and titers were compared between cohorts, and associations with clinical subphenotypes and anti-EPCR were examined. RESULTS: Anti-αvβ6 positivity was significantly higher in UC patients (85.4%) than in CD patients (16.4%) or control subjects (0%). Within UC, high positivity was observed across all disease extents, with only minor cohort differences. Longer disease duration was associated with lower positivity in both cohorts. In CD, the U.S. cohort showed higher positivity (23.4%) than the Japanese cohort (10.1%), particularly in colonic CD. Absence of ileal involvement, strictures, or perianal disease was associated with higher positivity. Anti-αvβ6 and anti-EPCR levels were strongly correlated, but their expression patterns differed in primary sclerosing cholangitis-associated IBD. Combining anti-αvβ6 and anti-EPCR improved UC diagnostic accuracy (area under the curve, 0.98; 95% confidence interval, 0.95-1.00) over either antibody alone (P = .00264). CONCLUSIONS: Anti-αvβ6 is a valuable biomarker for UC diagnosis. However, this study demonstrated differences in its behavior between U.S. and Japanese cohorts, particularly in CD. Cohort-informed interpretation and combined antibody testing may improve diagnostic precision and disease stratification in IBD.

  23. Phenotype, serotype, and data-driven clustering reveal complementary dimensions of heterogeneity in ANCA-associated vasculitis: a multicentre Japanese cohort (J-CANVAS). 国際誌

    Genki Kidoguchi, Yusuke Yoshida, Satoshi Omura, Daiki Nakagomi, Yoshiyuki Abe, Makoto Wada, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Hirosuke Takagi, Koji Endo, Naoto Azuma, Tohru Takeuchi, Shoichi Fukui, Kazuro Kamada, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki Takata, Mayuko Moriyama, Ayuko Takatani, Yoshia Miyawaki, Tsuyoshi Shirai, Hiroaki Dobashi, Takafumi Ito, Isao Matsumoto, Toshihiko Takada, Yutaka Kawahito, Toshiko Ito-Ihara, Takashi Kida, Nobuyuki Yajima, Takashi Kawaguchi, Shintaro Hirata

    Rheumatology international　45　(12)　272-272　2025年11月12日

    DOI： 10.1007/s00296-025-06014-y 　

    詳細を見る 詳細を閉じる

    OBJECTIVE: To compare clinicopathological phenotype-based, anti-neutrophil cytoplasmic antibody (ANCA) serotype-based, and unsupervised data-driven classifications in relation to clinical outcomes and patient heterogeneity in a large Japanese cohort with ANCA-associated vasculitis (AAV). METHODS: This multicentre, retrospective cohort study analysed data from a nationwide Japanese registry of 729 newly diagnosed patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), all positive for myeloperoxidase (MPO)- or proteinase 3 (PR3)-ANCA. Patients were classified by phenotype, serotype, combined phenotype-serotype groupings, and data-driven clustering based on baseline clinical and laboratory features. Associations with clinical outcomes-including mortality, relapse, and response to rituximab (RTX) versus cyclophosphamide (IVCY)-were evaluated using inverse probability of treatment weighting (IPW). RESULTS: Phenotype-based classification more accurately distinguished all-cause mortality risk (MPA vs. GPA: hazard ratio [HR] 2.53, 95% CI 1.34-4.76). Combined phenotype-serotype analysis identified MPO-MPA patients with the highest mortality (HR 3.45, 95% CI 1.09-11.0, vs. PR3-GPA) and PR3-GPA with the highest severe relapse. Discordant groups, such as MPO-GPA, demonstrated unique clinical characteristics. After IPW adjustment, no significant difference in 24-week remission rates was observed between RTX and IVCY across classifications, both overall (RR 1.02, 95% CI 0.95-1.09) and within subgroups. Unsupervised clustering identified four distinct clinical subgroups, with limited concordance with conventional phenotype or serotype classifications. CONCLUSION: Phenotype and serotype classifications provide complementary, not competing, prognostic insights in Japanese patients with AAV. Data-driven clustering revealed additional clinical heterogeneity not captured by traditional systems, underscoring the need for integrated, multi-dimensional stratification approaches to improve personalised risk assessment and treatment strategies.

  24. Increased prevalence of gastrointestinal involvement in Behçet’s syndrome patients with gynaecological disorders

    Isso Saito, Yusho Ishii, Hiroko Sato, Tsuyoshi Shirai, Hiroshi Fujii

    Modern Rheumatology　2025年10月28日

    DOI： 10.1093/mr/roaf048 　

  25. Autoantibodies against endothelial protein C receptor and integrin αvβ6 predict the development of ulcerative colitis.

    Motoi Sawahashi, Yoichi Kakuta, Takeo Naito, Soshi Okazaki, Kinuko Ohneda, Masatsugu Orui, Taku Obara, Soichi Ogishima, Kazuki Kumada, Hisaaki Kudo, Fuji Nagami, Atsushi Hozawa, Hideya Iwaki, Hiroshi Nagai, Yusuke Shimoyama, Rintaro Moroi, Hisashi Shiga, Yoshitaka Kinouchi, Tsuyoshi Shirai, Hiroshi Fujii, Atsushi Masamune

    Journal of gastroenterology　60　(9)　1108-1117　2025年9月

    DOI： 10.1007/s00535-025-02263-7 　

    詳細を見る 詳細を閉じる

    BACKGROUND: A method for predicting ulcerative colitis (UC) onset has not been established. Serum autoantibodies have been suggested as potential predictive biomarkers for UC onset. We aimed to validate the risks associated with serological and environmental factors and construct a model for predicting UC development. METHODS: Using the population-based cohort studies (n > 83,000), we identified 42 individuals who were diagnosed with UC later in life and compared them with matched healthy controls. We analyzed serum anti-integrin αvβ6 antibody (anti-αvβ6) and anti-endothelial protein C receptor antibody (anti-EPCR) titers, and lifestyle and dietary habits to explore UC onset predictors. The predictive performance of the models was evaluated based on these predictors. RESULTS: The sensitivity and specificity of anti-EPCR for predicting UC onset were 51.4% and 97.8%, respectively, comparable to those of anti-αvβ6 (52.5% and 97.6%, respectively). The proportion of individuals with insomnia was significantly higher in the preclinical UC group (adjusted odds ratio = 2.14, 95% confidence interval [CI] 1.11-4.04, p = 0.019). The predictive performance of anti-EPCR alone was high with an area under the curve (AUC) of 0.89 (95%CI 0.83-0.96), and that of anti-EPCR combined with anti-αvβ6 was even better with an AUC of 0.92 (95%CI 0.87-0.97); the lifestyle model had lower predictive accuracy (AUC = 0.65, 95%CI 0.55-0.74). CONCLUSIONS: Anti-EPCR and anti-αvβ6 each strongly predict UC onset. The combined anti-EPCR and anti-αvβ6 model had stronger predictive performance than the single models.

  26. Refractory skin ulcers and afebrile bacteraemia with Staphylococcus aureus in antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A case report

    Tokio Katakura, Tsuyoshi Shirai, Yusho Ishii, Hiroko Sato, Hiroshi Fujii

    Modern Rheumatology Case Reports　2025年7月25日

    DOI： 10.1093/mrcr/rxae082 　

  27. Drug-induced liver injury related to avacopan therapy

    Kentaro Mori, Tsuyoshi Shirai, Tomoyuki Mutoh, Jun Inoue, Fumiyoshi Fujishima, Satsuki Kubo, Hirofumi Watanabe, Satoko Sato, Mamoru Narita, Yosuke Hoshi, Hiroko Sato, Hiroshi Fujii

    Rheumatology　2025年5月1日

    DOI： 10.1093/rheumatology/keae689 　

  28. Positron Emission Tomography in Takayasu Arteritis: A Review Including Patterns of Vascular Involvement Across Modalities and Regions

    Tokio Katakura, Tsuyoshi Shirai

    Journal of Clinical Medicine　2025年4月24日

    DOI： 10.3390/jcm14092939 　

  29. Effectiveness and safety of low-energy shock wave therapy for digital ulcers associated with systemic sclerosis: A Phase 3 pivotal clinical trial. 国際誌

    Tomonori Ishii, Yasushi Kawaguchi, Osamu Ishikawa, Hiromitsu Takemori, Naruhiko Takasawa, Hitoshi Kobayashi, Yuichi Takahashi, Hidekata Yasuoka, Takao Kodera, Osamu Takai, Izaya Nakaya, Yukio Sato, Tomomasa Izumiyama, Hiroshi Fujii, Yukiko Kamogawa, Yuko Shirota, Tsuyoshi Shirai, Yoko Fujita, Shinichiro Saito, Shih-Wei Chiu, Takuhiro Yamaguchi, Hiroaki Shimokawa, Hideo Harigae

    Modern rheumatology　35　(3)　484-495　2025年4月8日

    DOI： 10.1093/mr/roae104 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: Systemic sclerosis (SSc) is characterised by ischaemic skin ulcers on the fingertips, and low-energy shock wave therapy is suggested as a novel treatment for ischaemic lesions with angiogenic effects. We aimed to investigate the efficacy and safety of shock wave therapy for skin ulcers in patients with SSc. METHODS: In this Phase 3 pivotal study, we analysed 60 SSc patients with digital ulcers that did not disappear after >4 weeks of existing treatment: 30 patients were treated with extracorporeal shock wave therapy and 30 with conventional treatment. The ulcer count reduction observed after an 8-week treatment period was compared between the shock wave therapy and conventional treatment groups. RESULTS: After an 8-week treatment period, the mean reduction in the number of ulcers was 0.83 (SD 2.79) in the conventional treatment group compared to a more pronounced reduction of 4.47 (SD 2.65) in the shock wave therapy group. CONCLUSIONS: The study findings indicate the efficacy of extracorporeal shock wave therapy for refractory digital ulcers associated with SSc, which has limited therapeutic options. This therapy is non-invasive and safe and can be used without restriction in combination with other therapies, thus serving as a novel therapeutic method.

  30. Clinical Images: Multiple blisters on the upper and lower extremities in granulomatosis with polyangiitis

    Tokio Katakura, Tsuyoshi Shirai, Hiroshi Fujii, Kenta Oka, Yoshihide Asano

    ACR Open Rheumatology　2025年3月

    DOI： 10.1002/acr2.70031 　

  31. Rheumatoid Factor Predicts Long‐Term Retention Associated With Effectiveness of Certolizumab Pegol in Patients With Rheumatoid Arthritis: A Two‐Center Retrospective Study

    Tomoyuki Mutoh, Soshi Okazaki, Tsuyoshi Shirai, Hiroko Sato, Susumu Ohtsu, Tomonori Ishii, Hiroshi Fujii

    International Journal of Rheumatic Diseases　2025年3月

    DOI： 10.1111/1756-185X.70173 　

  32. Enthesitis as an initial presentation of vascular Behçet's syndrome: a case-based review. 国際誌

    Isso Saito, Tsuyoshi Shirai, Hiroko Sato, Tomonori Ishii, Hiroshi Fujii

    Rheumatology international　44　(11)　2637-2643　2024年11月

    DOI： 10.1007/s00296-024-05607-3 　

    詳細を見る 詳細を閉じる

    Enthesitis is a characteristic manifestation of spondyloarthropathy (SpA). Historically, Behçet's syndrome (BS) was classified within SpA. Although they are now classified separately, the association between BS and SpA remains controversial. The concept of MHC-I (major histocompatibility complex class I)-opathy has been proposed based on the overlap in immunopathological mechanisms among diseases associated with human leukocyte antigen (HLA) class I. Enthesitis is a frequent complication in patients with BS who also have acne and arthritis. However, information regarding enthesitis in patients with BS without arthritis (BS-WA) is limited. Herein, we report a case of vascular BS complicated by enthesitis. In this case, heel pain was the dominant symptom at presentation. Laboratory tests revealed chlamydia antibody positivity, leading to a tentative diagnosis of reactive arthritis. Despite treatment, C-reactive protein (CRP) levels remained elevated. Imaging revealed numerous aneurysmal lesions in the large vessels. Based on these findings and other symptoms, patient was diagnosed with vascular BS. He tested positive for HLA-B15 and HLA-B46, which are associated with peripheral SpA. Subsequent remission induction therapy for BS was effective and the patient was discharged without complications. Our case and a literature review suggest that there exists a subgroup of BS-WA with a complication of enthesitis, possibly belonging to the spectrum of MHC-I-opathies. It is important to consider BS as a differential diagnosis in patients presenting with enthesitis and to conduct a precise medical history review regarding the symptoms of BS.

  33. 非典型的な臨床経過と腎病理を呈した多発血管炎性肉芽腫症

    木之村 聡介, 豊原 敬文, 白井 剛志, 秋保 真穂, 菊地 晃一, 牧野 塁, 吉田 舞, 大江 佑治, 岡本 好司, 長澤 将, 宮崎 真理子, 佐藤 博, 藤井 博司, 田中 哲洋

    日本腎臓学会誌　66　(6-E)　957-957　2024年9月

    出版者・発行元： (一社)日本腎臓学会

    ISSN：0385-2385

    eISSN：1884-0728

  34. Successful management of interstitial lung disease in dermatomyositis complicated by malignancy: a case-based review. 国際誌

    Tokio Katakura, Tsuyoshi Shirai, Hiroko Sato, Tomonori Ishii, Hiroshi Fujii

    Rheumatology international　44　(9)　1781-1788　2024年9月

    DOI： 10.1007/s00296-023-05442-y 　

    詳細を見る 詳細を閉じる

    Dermatomyositis (DM) is associated with interstitial lung disease (ILD) and malignancy. However, the coexistence of ILD and malignancy (DM-ILD-malignancy) is rare, and limited information exists regarding its management. Herein, we report the case of a 70-year-old man who developed DM with rapidly progressive ILD and advanced gastric cancer and provide a literature review of managing DM-ILD-malignancy. The patient presented with typical DM skin rashes and shortness of breath, which worsened within 1 month, without muscular symptoms. Additionally, the patient tested negative for myositis-specific autoantibodies (MSAs). Computed tomography revealed ILD and advanced gastric cancer, which was confirmed on endoscopic examination to be a poorly differentiated adenocarcinoma. Although the patient's ILD progressed rapidly, surgical treatment of the cancer was prioritized. Prednisolone (PSL) 0.5 mg/kg was initiated 3 days before surgery and increased to 1 mg/kg at 7 days postoperative. Remarkable improvement in the skin rash and ILD was observed, and the PSL dose was tapered without immunosuppressants. A literature review revealed that anti-melanoma differentiation-associated gene 5 and anti-aminoacyl transfer RNA synthetase antibodies are the predominant MSAs in DM-ILD-malignancy, and the optimal treatment should be determined based on several factors, including ILD patterns, and malignancy type and stage. In particular, lung cancer may be a risk factor for the acute exacerbation of ILD, and preceding immunosuppression would be useful. Furthermore, prioritizing surgery for gastric cancer is effective because of its paraneoplastic nature.

  35. Development of anti-MDA5 autoantibody-positive dermatomyositis following the use of etanercept biosimilar in rheumatoid arthritis. 国際誌

    Soshi Okazaki, Tsuyoshi Shirai, Hiroko Sato, Tomonori Ishii, Hiroshi Fujii

    Modern rheumatology case reports　8　(2)　296-301　2024年7月8日

    DOI： 10.1093/mrcr/rxae013 　

    詳細を見る 詳細を閉じる

    The induction of autoimmune diseases during tumour necrosis factor-alpha inhibitor (TNFi) usage has been described. Herein, we report a rare case of a 49-year-old woman with antimelanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive dermatomyositis (DM), which developed 5 weeks after the introduction of an etanercept biosimilar to rheumatoid arthritis (RA). Four of the five known cases, including ours, of anti-MDA5Ab-positive DM complicated with RA revealed anti-MDA5Ab-positive DM following TNFi usage. When patients with RA are diagnosed with interstitial lung disease during TNFi usage, anti-MDA5 Ab-positive DM could be a differential diagnosis.

  36. Comment on: A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. 国際誌

    Sae Shirota, Tsuyoshi Shirai, Kentaro Mori, Jun Inoue, Hiroko Sato, Tomonori Ishii, Hiroshi Fujii

    Rheumatology (Oxford, England)　63　(4)　e149-e150　2024年4月2日

    DOI： 10.1093/rheumatology/kead561 　

  37. 中小型血管炎:治療3 アバコパン導入ANCA関連血管炎における薬物性肝障害の検討

    森 健太郎, 白井 剛志, 武藤 智之, 成田 衛, 星 陽介, 町山 智章, 石井 悠翔, 佐藤 紘子, 石井 智徳, 藤井 博司

    日本リウマチ学会総会・学術集会プログラム・抄録集　68回　582-582　2024年3月

    出版者・発行元： (一社)日本リウマチ学会

  38. 中小型血管炎:臨床(治療を除く)2 本邦ANCA関連血管炎患者における2022年ACR/EULAR新分類基準の有用性に関する検討

    桑田 亮, 城田 祐子, 白井 剛志, 山下 裕之, 佐藤 紘子, 岡 友美子, 小寺 隆雄, 本村 杏子, 金子 礼志, 亀岡 淳一, 藤井 博司, 石井 智徳

    日本リウマチ学会総会・学術集会プログラム・抄録集　68回　584-584　2024年3月

    出版者・発行元： (一社)日本リウマチ学会

  39. 全身性エリテマトーデスにおけるベリムマブの有効性と代謝マーカーへの影響

    大和 真弥, 白井 剛志, 佐藤 紘子, 石井 智徳, 藤井 博司

    日本リウマチ学会総会・学術集会プログラム・抄録集　68回　907-907　2024年3月

    出版者・発行元： (一社)日本リウマチ学会

  40. 中小型血管炎:治療3 アバコパン導入ANCA関連血管炎における薬物性肝障害の検討

    森 健太郎, 白井 剛志, 武藤 智之, 成田 衛, 星 陽介, 町山 智章, 石井 悠翔, 佐藤 紘子, 石井 智徳, 藤井 博司

    日本リウマチ学会総会・学術集会プログラム・抄録集　68回　582-582　2024年3月

    出版者・発行元： (一社)日本リウマチ学会

  41. 中小型血管炎:臨床(治療を除く)2 本邦ANCA関連血管炎患者における2022年ACR/EULAR新分類基準の有用性に関する検討

    桑田 亮, 城田 祐子, 白井 剛志, 山下 裕之, 佐藤 紘子, 岡 友美子, 小寺 隆雄, 本村 杏子, 金子 礼志, 亀岡 淳一, 藤井 博司, 石井 智徳

    日本リウマチ学会総会・学術集会プログラム・抄録集　68回　584-584　2024年3月

    出版者・発行元： (一社)日本リウマチ学会

  42. 全身性エリテマトーデスにおけるベリムマブの有効性と代謝マーカーへの影響

    大和 真弥, 白井 剛志, 佐藤 紘子, 石井 智徳, 藤井 博司

    日本リウマチ学会総会・学術集会プログラム・抄録集　68回　907-907　2024年3月

    出版者・発行元： (一社)日本リウマチ学会

  43. Impact of subcutaneous belimumab on disease activity, patient satisfaction, and metabolic profile in long-lasting systemic lupus erythematosus

    Maya Yamato, Tsuyoshi Shirai, Yusho Ishii, Hiroko Sato, Tomonori Ishii, Hiroshi Fujii

    Clinical Rheumatology　2024年2月9日

    出版者・発行元： Springer Science and Business Media LLC

    DOI： 10.1007/s10067-024-06904-9 　

    ISSN：0770-3198

    eISSN：1434-9949

  44. Active withdrawal of corticosteroids using tocilizumab and its association with autoantibody profiles in relapsed Takayasu arteritis: a multicentre, single-arm, prospective study (the Ab-TAK study). 国際誌

    Tsuyoshi Shirai, Tomonori Ishii, Soshi Okazaki, Yuko Shirota, Yusho Ishii, Hiroko Sato, Hiroshi Fujii

    Frontiers in immunology　15　1473100-1473100　2024年

    DOI： 10.3389/fimmu.2024.1473100 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: The feasibility of corticosteroid withdrawal (CW) for Takayasu arteritis (TAK) remains uncertain. Two autoantibodies (Abs) are identified against endothelial protein C receptor (EPCR) and scavenger receptor class B type 1 (SR-BI) in TAK, determining its three subgroups. This study aimed to evaluate CW using tocilizumab (TCZ) and its association with the Ab profile. METHODS: This prospective study, lasted for 24 weeks, included patients with relapsed but stable TAK. Scheduled tapering of prednisolone (PSL) was performed with subcutaneous TCZ (CW at week 20). The primary endpoint was the difference in type A remission, defined by CW and the absence of inflammatory signs, according to the Ab profile at week 24. RESULTS: Twenty patients were included and 18 patients with a mean PSL dose of 4.9 ± 2.8 mg/day were analysed. Anti-EPCR Ab-positive (E+), anti-SR-BI Ab-positive (S+), and double-negative (DN) groups included four (22.2%), eight (44.4%), and six (33.3%) patients, respectively. At week 24, the mean PSL dose was 2.0 ± 2.7 mg/day. Type A remission was observed in eight patients (44.4%), with significant differences based on the Ab profile: E+ (three patients, 75%), S+ (five patients, 62.5%), and DN (zero patients, 0%) (P=0.018). Besides, age, disease duration, PSL dose, type V arterial lesion, arterial dilation, and C-reactive protein >0.01 mg/dL were identified as risks for CW failure. CONCLUSION: CW using TCZ was achieved in 44.4% of patients with TAK relapse and was significantly higher in E+ and S+ patients. CW can be a feasible target, and the precise selection of patients is critical.

  45. Phospholipase D4 as a signature of toll-like receptor 7 or 9 signaling is expressed on blastic T-bet + B cells in systemic lupus erythematosus. 国際誌

    Ken Yasaka, Tomohide Yamazaki, Hiroko Sato, Tsuyoshi Shirai, Minkwon Cho, Koji Ishida, Koyu Ito, Tetsuhiro Tanaka, Kouetsu Ogasawara, Hideo Harigae, Tomonori Ishii, Hiroshi Fujii

    Arthritis research & therapy　25　(1)　200-200　2023年10月16日

    DOI： 10.1186/s13075-023-03186-5 　

    詳細を見る 詳細を閉じる

    BACKGROUND: In systemic lupus erythematosus (SLE), autoreactive B cells are thought to develop by-passing immune checkpoints and contribute to its pathogenesis. Toll-like receptor (TLR) 7 and 9 signaling have been implicated in their development and differentiation. Although some B cell subpopulations such as T-bet + double negative 2 (DN2) cells have been identified as autoreactive in the past few years, because the upregulated surface markers of those cells are not exclusive to them, it is still challenging to specifically target autoreactive B cells in SLE patients. METHODS: Our preliminary expression analysis revealed that phospholipase D4 (PLD4) is exclusively expressed in plasmacytoid dendritic cells (pDCs) and B cells in peripheral blood mononuclear cells (PBMCs) samples. Monoclonal antibodies against human PLD4 were generated, and flow cytometry analyses were conducted for PBMCs from 23 healthy donors (HDs) and 40 patients with SLE. In vitro cell culture was also performed to study the conditions that induce PLD4 in B cells from HDs. Finally, recombinant antibodies were synthesized from subpopulations of PLD4 + B cells from a patient with SLE, and their antinuclear activity was measured through enzyme-linked immunosorbent assay. RESULTS: pDCs from both groups showed comparable frequency of surface PLD4 expression. PLD4 + B cells accounted for only a few percent of HD B cells, whereas they were significantly expanded in patients with SLE (2.1% ± 0.4% vs. 10.8% ± 1.2%, P < 0.005). A subpopulation within PLD4 + B cells whose cell size was comparable to CD38 + CD43 + plasmablasts was defined as "PLD4 + blasts," and their frequencies were significantly correlated with those of plasmablasts (P < 0.005). PLD4 + blasts phenotypically overlapped with double negative 2 (DN2) cells, and, in line with this, their frequencies were significantly correlated with several clinical markers of SLE. In vitro assay using healthy PBMCs demonstrated that TLR7 or TLR9 stimulation was sufficient to induce PLD4 on the surface of the B cells. Finally, two out of three recombinant antibodies synthesized from PLD4 + blasts showed antinuclear activity. CONCLUSION: PLD4 + B cells, especially "blastic" ones, are likely autoreactive B cells undergoing TLR stimulation. Therefore, PLD4 is a promising target marker in SLE treatment.

  46. 全身性エリテマトーデスに対してステロイド治療開始後、強皮症腎クリーゼの併発が示唆された一例

    成田 衛, 星 陽介, 佐藤 紘子, 白井 剛志, 金銅 妃奈子, 石井 智徳, 田中 哲弘, 藤井 博司

    日本リウマチ学会北海道・東北支部学術集会抄録集　33回　57-57　2023年9月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  47. 若年・成人の境界年齢に発症しマクロファージ活性化症候群を呈したStill病の一例

    松崎 凌佑, 白井 剛志, 佐藤 紘子, 星 陽介, 矢坂 健, 森 健太郎, 成田 衛, 石井 智徳, 藤井 博司

    日本リウマチ学会北海道・東北支部学術集会抄録集　33回　76-76　2023年9月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  48. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome. 国際誌 査読有り

    Ayaka Maeda, Naomi Tsuchida, Yuri Uchiyama, Nobuyuki Horita, Satoshi Kobayashi, Mitsumasa Kishimoto, Daisuke Kobayashi, Haruki Matsumoto, Tomoyuki Asano, Kiyoshi Migita, Ayaka Kato, Ichiro Mori, Hiroyuki Morita, Akihiro Matsubara, Yoshiaki Marumo, Yuji Ito, Tomoaki Machiyama, Tsuyoshi Shirai, Tomonori Ishii, Mari Kishibe, Yusuke Yoshida, Shintaro Hirata, Satoshi Akao, Akitsu Higuchi, Ryo Rokutanda, Ken Nagahata, Hiroki Takahashi, Koske Katsuo, Toshio Ohtani, Hiroshi Fujiwara, Hiromichi Nagano, Takashi Hosokawa, Takanori Ito, Yoichiro Haji, Hiroyuki Yamaguchi, Noboru Hagino, Toshimasa Shimizu, Tomohiro Koga, Atsushi Kawakami, Goichi Kageyama, Hiroshi Kobayashi, Akiko Aoki, Akinari Mizokami, Yoichi Takeuchi, Rena Motohashi, Hiroyuki Hagiyama, Masaki Itagane, Hiroyuki Teruya, Tomohiro Kato, Yuji Miyoshi, Takayasu Kise, Naoto Yokogawa, Takako Ishida, Naoki Umeda, Shuntaro Isogai, Taio Naniwa, Toru Yamabe, Kaori Uchino, Jo Kanasugi, Akiyoshi Takami, Yasushi Kondo, Kazunori Furuhashi, Koichi Saito, Shigeru Ohno, Daiga Kishimoto, Mari Yamamoto, Yoshiro Fujita, Yuichiro Fujieda, Sachiko Araki, Hiroshi Tsushima, Kyohei Misawa, Akira Katagiri, Takahiro Kobayashi, Kenichi Hashimoto, Takehiro Sone, Yukiko Hidaka, Hiroaki Ida, Ryuta Nishikomori, Hiroshi Doi, Katsumichi Fujimaki, Keiichi Akasaka, Masako Amano, Hidekazu Matsushima, Kaori Kashino, Hidenori Ohnishi, Yuki Miwa, Noriyuki Takahashi, Kaoru Takase-Minegishi, Ryusuke Yoshimi, Yohei Kirino, Hideaki Nakajima, Naomichi Matsumoto

    Rheumatology (Oxford, England)　2023年8月22日

    DOI： 10.1093/rheumatology/kead425 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: To efficiently detect somatic UBA1 variants and establish a clinical scoring system predicting patients with pathogenic variants in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. METHODS: Eighty-nine Japanese patients with clinically suspected VEXAS syndrome were recruited [81 males and 8 females; median onset age (IQR) 69.3 years (62.1-77.6)]. Peptide nucleic acid-clamping PCR (PNA-PCR), regular PCR targeting exon 3 clustering UBA1 variants, and subsequent Sanger sequencing were conducted for variant screening. Partitioning digital PCR (pdPCR) or targeted amplicon deep sequencing (TAS) was also performed to evaluate the variant allele frequency (VAF). We developed our clinical scoring system to predict UBA1 variant-positive and ‑negative patients and assessed the diagnostic value of our system using receiver operating characteristic (ROC) curve analysis. RESULTS: Forty patients with reported pathogenic UBA1 variants (40/89, 44.9%) were identified, including a case having a variant with VAF of 1.7%, using a highly sensitive method. Our clinical scoring system considering >50 years of age, cutaneous lesions, lung involvement, chondritis, and macrocytic anaemia efficiently predicted patients with UBA1 variants (the area under the curve for the scoring total was 0.908). CONCLUSIONS: Genetic screening with the combination of regular PCR and PNA-PCR detected somatic UBA1 variants with high sensitivity and specificity. Our scoring system could efficiently predict patients with UBA1 variants.

  49. First reported case of pulmonary arteritis in patients with relapsing polychondritis 国際誌

    Maya Yamato, Tsuyoshi Shirai, Hiroko Sato, Tomonori Ishii, Hiroshi Fujii

    Rheumatology　2023年6月16日

    DOI： 10.1093/rheumatology/kead300 　

  50. 【分類不能腸炎(IBDU)の現状と将来展望】炎症性腸疾患における血清学的バイオマーカー診断の現状

    角田 洋一, 岡崎 創司, 澤橋 基, 猪股 優志, 下山 雄丞, 内藤 健夫, 諸井 林太郎, 志賀 永嗣, 木内 喜孝, 白井 剛志, 藤井 博司, 正宗 淳

    胃と腸　58　(6)　783-788　2023年6月

    出版者・発行元： (株)医学書院

    ISSN：0536-2180

    eISSN：1882-1219

  51. Severe Bone Marrow Aplasia Following Macrophage Activation Syndrome in Systemic Lupus Erythematosus.

    Hirona Ichimura, Satoshi Ichikawa, Koya Ono, Kyoko Inokura, Yosuke Hoshi, Tsuyoshi Shirai, Noriko Fukuhara, Hisayuki Yokoyama, Hiroshi Fujii, Hideo Harigae

    The Tohoku journal of experimental medicine　260　(4)　301-304　2023年5月11日

    DOI： 10.1620/tjem.2023.J037 　

    詳細を見る 詳細を閉じる

    Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases, characterized by activated macrophages with hemophagocytosis and multiple organ damage. We report a case of MAS associated with systemic lupus erythematosus that initially presented with severe liver dysfunction. Although it was improved with steroids and plasmapheresis, severe pancytopenia was subsequently experienced, and the bone marrow showed severe aplasia similar to aplastic anemia. Nevertheless, the administration of immunosuppressants resulted in the recovery of blood counts within two weeks. When severe MAS results in cytokine overproduction, bone marrow aplasia may occur, for which immunosuppressive therapy may be highly effective.

  52. Dysbiosis in Takayasu arteritis complicated with infectious endocarditis following tocilizumab administration

    T Shirai, H Sato, T Ishii, H Fujii

    Scandinavian Journal of Rheumatology　2023年3月4日

    DOI： 10.1080/03009742.2022.2124620 　

  53. ANCA関連血管炎の診断 従来法で診断された本邦多発血管炎性肉芽症患者における2022年アメリカリウマチ学会/ヨーロッパリウマチ学会新分類基準の有用性に関する検討

    桑田 亮, 城田 祐子, 白井 剛志, 山下 裕之, 佐藤 紘子, 武田 朋樹, 岡 友美子, 小寺 隆雄, 金子 礼志, 亀岡 淳一, 藤井 博司, 石井 智徳

    日本リウマチ学会総会・学術集会プログラム・抄録集　67回　524-524　2023年3月

    出版者・発行元： (一社)日本リウマチ学会

  54. 多発性筋炎・皮膚筋炎1:抗MDA5抗体陽性症例のアウトカム 抗MDA5抗体陽性皮膚筋炎の中長期的予後の検討

    白井 剛志, 片倉 世雄, 森 健太郎, 井樋 創, 星 陽介, 高橋 秀典, 町山 智章, 佐藤 紘子, 石井 智徳, 藤井 博司

    日本リウマチ学会総会・学術集会プログラム・抄録集　67回　535-535　2023年3月

    出版者・発行元： (一社)日本リウマチ学会

  55. 多発性筋炎・皮膚筋炎4:抗MDA5抗体/抗ARS抗体陰性の多発性筋炎/皮膚筋炎 抗TIF-1γ抗体陽性皮膚筋炎の臨床的特徴と再燃率の検討

    片倉 世雄, 森 健太郎, 高橋 幹弘, 矢坂 健, 井樋 創, 星 陽介, 高橋 秀典, 佐藤 紘子, 白井 剛志, 石井 智徳, 藤井 博司

    日本リウマチ学会総会・学術集会プログラム・抄録集　67回　641-641　2023年3月

    出版者・発行元： (一社)日本リウマチ学会

  56. 馬蹄腎に発症し,尿所見と腎病理像に乖離を認めたANCA関連腎炎の一例

    森 健太郎, 片倉 世雄, 高橋 幹弘, 井樋 創, 星 陽介, 高橋 秀典, 町山 智章, 佐藤 紘子, 白井 剛志, 石井 智徳, 藤井 博司

    日本リウマチ学会総会・学術集会プログラム・抄録集　67回　842-842　2023年3月

    出版者・発行元： (一社)日本リウマチ学会

  57. Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associatedprotein-5 antibody-positive dermatomyositis. 国際誌

    Tsuyoshi Shirai, Tomoaki Machiyama, Hiroko Sato, Tomonori Ishii, Hiroshi Fujii

    Clinical and experimental rheumatology　41　(2)　291-300　2023年3月

    DOI： 10.55563/clinexprheumatol/8kulbf 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: Anti-melanoma differentiation-associated protein-5 (MDA5) autoantibodies (Abs) are associated with rapidly progressive interstitial lung disease (RP-ILD) in dermatomyositis (DM). Because the addition of plasma exchange (PE) and rituximab (RTX) to triple therapy is inadequate in severe cases, we treat such cases with intensive induction therapy (IIT) combining all these options with tofacitinib (TOF). In this study, we investigated the poor prognostic factors and the efficacy and safety of IIT. METHODS: Thirty-three patients diagnosed with anti-MDA5 Ab-positive DM in our institution between 2014 and 2021 were included. The clinical characteristics of poor prognosis were retrospectively analysed using principal component analysis (PCA), and the outcomes of IIT were analysed in terms of survival, assessed using the Kaplan-Meier test, and adverse events. RESULTS: Although triple therapy with RTX, PE, or intravenous immunoglobulin was administered before the introduction of IIT, eight of 12 RP-ILD cases with a ferritin level >400 ng/mL (mean, 2,342) died within a median of 2.5 months. PCA revealed distinct clusters for prognosis, and age and serum ferritin were leading predictors of the prognosis. IIT, consisting of combinations of triple therapy with higher doses of methylprednisolone, PE, RTX, and TOF, was applied to eight patients (mean ferritin, 3,558). Although two patients died even with these regimens, a significant improvement in survival was documented. Several IIT-related adverse events were observed, including viral and fungal infections and cytopenia. CONCLUSIONS: IIT significantly improved the survival of patients with severe anti-MDA5 Ab-positive RP-ILD. Although infections are noted, their benefits outweigh the risks in younger patients with high serum ferritin levels.

  58. Common Autoantibody among Takayasu Arteritis and Ulcerative Colitis: A Possible Pathophysiology That Includes Gut-Vessel Connection in Vascular Inflammation 査読有り

    Tsuyoshi Shirai

    JMA Journal　6　(3)　2023年

    出版者・発行元： Japan Medical Association

    DOI： 10.31662/jmaj.2023-0038 　

    ISSN：2433-3298 2433-328X

  59. Sjögren's Syndrome Presenting with Temporary Hemiplegia Mimicking Transient Ischemic Attack.

    Yukiko Kamogawa, Kanae Akita, Hiroko Sato, Tsuyoshi Shirai, Tomonori Ishii, Hideo Harigae, Hiroshi Fujii

    The Tohoku journal of experimental medicine　258　(3)　207-211　2022年10月26日

    DOI： 10.1620/tjem.2022.J079 　

    詳細を見る 詳細を閉じる

    Sjögren's syndrome manifests with a wide variety of neurologic symptoms. This case report presents a 53-year-old woman with Sjögren's syndrome associated with temporal hemiplegia, which was suspected to be a transient ischemic attack. After induction of immunosuppressive therapies [high-dose prednisolone (1 mg/kg/day) and intravenous cyclophosphamide (total 5 g)], the hemiplegia did not reappear and the blood flow abnormalities remarkably improved as depicted on electroencephalography and single photon emission computed tomography. This case suggests that temporal hemiplegia presenting with transient ischemia-like attack symptoms may be a neurologic manifestation of Sjögren's syndrome and responsive to immunosuppressive therapy.

  60. IBD病態を踏まえた今後の治療ストラテジー 抗EPCR抗体価と潰瘍性大腸炎の病態および治療反応性との関連に関する検討

    角田 洋一, 白井 剛志, 正宗 淳

    Gastroenterological Endoscopy　64　(Suppl.2)　2023-2023　2022年10月

    出版者・発行元： (一社)日本消化器内視鏡学会

    ISSN：0387-1207

    eISSN：1884-5738

  61. 腰痛で発症,経過中洞停止をきたし,シクロフォスファミドパルスが奏功した抗ミトコンドリア抗体陽性皮膚筋炎の一例

    高橋 幹弘, 武藤 智之, 永井 泰地, 佐藤 紘子, 白井 剛志, 石井 智徳, 藤井 博司

    日本リウマチ学会北海道・東北支部学術集会抄録集　32回　43-43　2022年9月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  62. 限局皮膚硬化型全身性強皮症に合併しinhibitor boostingによる血漿交換不応が疑われた血栓性血小板減少性紫斑病の一例

    森 健太郎, 片倉 世雄, 高橋 幹弘, 高橋 秀典, 星 陽介, 佐藤 紘子, 白井 剛志, 石井 智徳, 藤井 博司

    日本リウマチ学会北海道・東北支部学術集会抄録集　32回　52-52　2022年9月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  63. Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells

    Ken Yasaka, Tomohide Yamazaki, Hiroko Sato, Tsuyoshi Shirai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　74　3240-3242　2022年9月

    ISSN：2326-5191

    eISSN：2326-5205

  64. 今月の症例 自己免疫性膵炎に対するステロイド維持療法中にIgG4関連下垂体炎を発症した1例

    大黒 顕佑, 尾股 慧, 手塚 雄太, 小野 美澄, 森本 玲, 白井 剛志, 宮崎 真理子, 張替 秀郎, 佐藤 文俊

    日本内科学会雑誌　111　(8)　1588-1593　2022年8月

    出版者・発行元： (一社)日本内科学会

    ISSN：0021-5384

    eISSN：1883-2083

    詳細を見る 詳細を閉じる

    67歳男性。自己免疫性膵炎に対するステロイド維持療法中に口渇、多尿、視野障害が出現し、当科へ精査入院となった。入院時、血中IgG4の再上昇、下垂体腫大に加え、汎下垂体前葉機能低下症、中枢性尿崩症を認めたことから、IgG4関連下垂体炎と診断された。治療として高用量のステロイド治療を行った結果、下垂体腫大の軽減、視野障害の消失、下垂体機能の部分的な回復が得られた。

  65. Establishing clinical remission criteria and the framework of a treat-to-target algorithm for Takayasu arteritis: Results of a Delphi exercise carried out by an expert panel of the Japan Research Committee of the Ministry of Health, Labour and Welfare for intractable vasculitis

    Takahiko Sugihara, Yoshikazu Nakaoka, Haruhito A. Uchida, Hajime Yoshifuji, Yasuhiro Maejima, Yoshiko Watanabe, Eisuke Amiya, Kazuo Tanemoto, Tetsuro Miyata, Natsuka Umezawa, Yusuke Manabe, Jun Ishizaki, Tsuyoshi Shirai, Hiroko Nagafuchi, Hitoshi Hasegawa, Takako Miyamae, Hiroaki Niiro, Shuichi Ito, Tomonori Ishii, Mitsuaki Isobe, Masayoshi Harigai

    MODERN RHEUMATOLOGY　32　(5)　930-937　2022年8月

    DOI： 10.1093/mr/roab081 　

    ISSN：1439-7595

    eISSN：1439-7609

  66. Presence of Phlebitis in Aseptic Nasal Septal Abscess Complicated with Ulcerative Colitis; Possible Association with Granulomatosis with Polyangiitis: A Case Report. 査読有り

    Tomohiko Ishikawa, Jun Suzuki, Tsuyoshi Shirai, Shotaro Koizumi, Yoshinori Tsuchiya, Kasumi Hishinuma, Yasuhiro Nakamura, Yukio Katori

    The Tohoku journal of experimental medicine　258　(1)　29-34　2022年6月30日

    DOI： 10.1620/tjem.2022.J053 　

    詳細を見る 詳細を閉じる

    Although nasal septal abscesses are uncommon, their cosmetic complications can be severe. Hence, prompt diagnosis and treatment are important. Here, we report a case of aseptic nasal septal abscess in a patient with proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA)-positive ulcerative colitis (UC), in which phlebitis was observed and granulomatosis with polyangiitis (GPA) might co-exist. A 27-year-old female suffered from intermittent abdominal pain and diarrhea for several years. She visited our hospital complaining of worsening swelling and pain in the middle forehead and fever lasting 2 weeks. Physical examination and computed tomography revealed severe swelling of the nasal septum. The patient was diagnosed with nasal septal abscess, and incision drainage and biopsy from the bilateral nasal septum were performed, which showed severe ulcerative neutrophilic mucositis with phlebitis. Simultaneously, blood examination yielded slight positivity for PR3-ANCA. Colonoscopy, including biopsy, revealed severe inflammation without vasculitis nor granuloma, which led to the diagnosis with PR3-ANCA-positive UC. Phlebitis in the nasal mucosa and elevated PR3-ANCA suggested co-existing GPA; hence, she was treated with glucocorticoids and rituximab. Following treatment, the nasal septal abscess and digestive symptoms disappeared. She was discharged on day 25 without symptom recurrence or major nasal deformity. For the prevention of nasal deformity due to persistent inflammation, prompt administration of immunosuppressive therapy should be considered with adequate evaluations for systemic diseases, including UC and GPA.

  67. Development of severe colitis in Takayasu arteritis treated with tocilizumab. 国際誌

    Kae Ishii, Tsuyoshi Shirai, Yoichi Kakuta, Tomoaki Machiyama, Hiroko Sato, Tomonori Ishii, Hideo Harigae, Hiroshi Fujii

    Clinical rheumatology　41　(6)　1911-1918　2022年6月

    DOI： 10.1007/s10067-022-06108-z 　

    詳細を見る 詳細を閉じる

    Relapse of Takayasu arteritis (TAK) is frequent, and the use of biologics is required in refractory cases. Tocilizumab (TCZ), a biological agent used in TAK, is known to increase the incidence of diverticulitis in patients with rheumatoid arthritis. Adverse events of TCZ in TAK have been poorly recognised. This study aimed to investigate the occurrence of severe colitis among patients with TAK receiving TCZ. We enrolled 116 patients with TAK who met the criteria of the American College of Rheumatology and visited our department between 2018 and 2020. The occurrence of severe colitis and its clinical characteristics were retrospectively evaluated. TCZ was introduced in 34 of 116 patients (29.3%). Severe colitis that required hospitalisation was observed in three of the 34 patients receiving TCZ (8.8%). All patients were female and had Numano type V artery lesions, and the ascending colon was commonly affected. Wide lesions that reached the sigmoid colon, colonic perforation, bacteraemia, or positive stool cultures were observed in some patients. All patients received antibiotics and intestinal rest, and TCZ was resumed in one patient. IL-6 plays a physiological role in the intestine, including recovery from ischaemic damage. In addition to infectious aetiology, blocking the physiological roles of IL-6 by TCZ is considered important for the development of colitis in TAK. Severe colitis is an important adverse event in patients with TAK who receive TCZ. The risk of bloodstream infection associated with colitis should be recognised, especially in patients who have undergone vascular surgery. Key Points • Severe colitis was observed in 8.8% of patients with TAK receiving tocilizumab • Patients had type V artery lesions and ascending colon involvement and were under long-term use of corticosteroids • Inhibition of the physiological roles of IL-6 in the intestinal tract might also be involved.

  68. Granulomatosis with Polyangiitis Following Pfizer-BioNTech COVID-19 Vaccination. 国際誌

    Tsuyoshi Shirai, Jun Suzuki, Shimpei Kuniyoshi, Yuito Tanno, Hiroshi Fujii

    Modern rheumatology case reports　7　(1)　127-129　2022年3月4日

    DOI： 10.1093/mrcr/rxac016 　

    詳細を見る 詳細を閉じる

    We report the first case of proteinase 3 (PR3)- antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (GPA) with predominant ears, nose, and throat (ENT) manifestations following COVID-19 vaccination. A 63-year-old woman presented with aural fullness three days after vaccination. She presented with progressive rhinosinusitis and otitis media leading to profound hearing loss within three weeks. Clinical imaging revealed soft-tissue shadows in the paranasal sinuses with multiple pulmonary nodules, and histopathology was consistent with a diagnosis of GPA. It is crucial to be wary of the possibility of GPA in patients who received COVID-19 vaccines due to its rapid disease progression.

  69. 高安動脈炎の臨床 高安動脈炎における生物学的製剤の長期的有効性と継続率の検討

    白井 剛志, 町山 智章, 佐藤 紘子, 藤井 博司, 石井 智徳

    日本リウマチ学会総会・学術集会プログラム・抄録集　66回　337-337　2022年3月

    出版者・発行元： (一社)日本リウマチ学会

  70. ANCA関連血管炎:コホート研究・ケースシリーズ 多発血管炎性肉芽腫症患者におけるANCAサブタイプの臨床的意義と免疫抑制療法効果の検討 多施設共同後方視的観察研究

    桑田 亮, 城田 祐子, 白井 剛志, 山下 裕之, 小林 俊昭, 本村 杏子, 金子 駿太, 高橋 裕子, 佐藤 紘子, 武田 朋樹, 堤 智美, 岡 友美子, 小寺 隆雄, 金子 礼志, 亀岡 淳一, 藤井 博司, 石井 智徳

    日本リウマチ学会総会・学術集会プログラム・抄録集　66回　415-415　2022年3月

    出版者・発行元： (一社)日本リウマチ学会

  71. 多発性筋炎・皮膚筋炎の治療 抗MDA5抗体陽性皮膚筋炎に対するトファシチニブ、血漿交換、リツキシマブを併用した高強度寛解導入療法の治療成績

    白井 剛志, 丹野 唯人, 星 陽介, 秋田 佳奈恵, 町山 智章, 佐藤 紘子, 藤井 博司, 石井 智徳

    日本リウマチ学会総会・学術集会プログラム・抄録集　66回　471-471　2022年3月

    出版者・発行元： (一社)日本リウマチ学会

  72. Predictive factors for retention of golimumab over a median 4-year duration in Japanese patients with rheumatoid arthritis in a real-world setting: A retrospective study and literature review. 国際誌

    Tomoyuki Mutoh, Taichi Nagai, Tsuyoshi Shirai, Soshi Okazaki, Hiroko Sato, Hiroshi Fujii

    International journal of rheumatic diseases　25　(3)　335-343　2022年3月

    DOI： 10.1111/1756-185X.14281 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: To investigate 6-year drug survival (median: 48.5 months) of golimumab and predictors for lack of efficacy leading to golimumab discontinuation in Japanese patients with rheumatoid arthritis (RA) in routine practice. METHODS: This retrospective single-center study included 60 patients with RA treated with golimumab from November 2011 to August 2020. Patients were divided into 2 groups (retention, n = 28; withdrawal due to lack of efficacy, n = 24). The retention rate was assessed using the Kaplan-Meier method, and variables associated with golimumab discontinuation were identified using the Cox proportional hazard model. RESULTS: The prevalence of concomitant methotrexate and no biologics use was significantly higher in the retention than in the withdrawal group. Overall drug survival of golimumab was 66.3%, 48.3%, and 24.5% at 12, 36, and 72 months, respectively. There were statistical differences in retention rates among groups stratified by initiation dose, methotrexate, and biologics use. Multivariate analysis revealed the factor associated with golimumab discontinuation as history of 1 (hazards ratio: 4.42, 95% CI: 1.35-19.93, P = .012) and ≥2 biologics use (7.49, 1.97-36.27, P = .003). CONCLUSIONS: Prior exposure of increasing number of biologics was identified as the most important factor negatively affecting long-term golimumab retention in Japanese patients with RA.

  73. Hypertrophic Pachymeningitis Development in Eosinophilic Granulomatosis with Polyangiitis at Relapse of Disease: A Case-Based Review.

    Machi Kiyohara, Tsuyoshi Shirai, Shuhei Nishiyama, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    The Tohoku journal of experimental medicine　256　(3)　241-247　2022年3月

    DOI： 10.1620/tjem.256.241 　

    詳細を見る 詳細を閉じる

    Hypertrophic pachymeningitis (HP) presents with thickening of the dura mater in the cerebrum and spine, and its symptoms vary depending on the affected location. The association of HP with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis has been recognized, and most cases are complicated by granulomatosis with polyangiitis. We report the case of a 47-year-old man who presented with HP upon relapse of eosinophilic granulomatosis with polyangiitis (EGPA), with literature review. He presented with disturbance of consciousness, and magnetic resonance imaging (MRI) revealed thickening of the dura mater around the left parietal lobe. Although myeloperoxidase (MPO)-ANCA was positive on EGPA diagnosis, the elevation of MPO-ANCA was not documented at the onset of HP. Brain perfusion scintigraphy showed an increase in blood flow in the left parietal lobe and temporal lobe, and electroencephalogram (EEG) revealed slow waves in the left parietal lobe. He was treated with a high dose of corticosteroid and rituximab, and the slow waves on EEG and brain perfusion were normalized. Although the most frequent symptom of HP is headache, disturbance of consciousness can be the manifestation of HP, and inflammation of HP could affect the cerebral parenchyma, which can be documented as abnormal EEG and perfusion scintigraphy. Literature review revealed that most of the HP in EGPA developed when EGPA relapsed, and was observed in patients with MPO-ANCA positivity. HP develops without evidence of other clinical features of EGPA; therefore, adequate imaging, including contrast-enhanced MRI, is necessary. Rituximab may be effective for treating HP complicated with EGPA.

  74. "Coexistence of IgA nephropathy and renal artery stenosis in Takayasu arteritis: case report and literature review". 国際誌

    Nono Ito, Tsuyoshi Shirai, Takafumi Toyohara, Hideaki Hashimoto, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    Rheumatology international　43　(2)　391-398　2022年1月11日

    DOI： 10.1007/s00296-021-05066-0 　

    詳細を見る 詳細を閉じる

    Although Takayasu arteritis (TAK) is a form of large vessel vasculitis, complications of glomerulonephritis have occasionally been observed, with mesangial proliferative glomerulonephritis as the most common. The aim of this work was to present a case-based review regarding the association of glomerulonephritis and IgA nephropathy (IgAN) with TAK. A literature search was carried out using the PubMed and Scopus databases for articles published in English, and the Ichu-shi Web for Japanese. A 34-year-old Japanese man was evaluated for proteinuria, and IgAN was diagnosed by renal biopsy. Simultaneously, aortic wall thickening and right renal artery stenosis confirmed a coexisting TAK. Prednisolone and methotrexate improved both diseases, and percutaneous transluminal renal angioplasty resulted in right renal artery reopening. Our case and literature review revealed that membranous proliferative glomerulonephritis and IgAN are common in eastern Asia, while focal segmental glomerulosclerosis and mesangial proliferative glomerulonephritis are common in other regions. The incidence of IgAN is higher in TAK cases and is mostly reported in Asia. Abdominal aortic involvement and renal artery stenosis are common in cases with preceding TAK. IgAN could be related to the cytokine network involving interleukin-6, suggesting the usefulness of tocilizumab in patients with TAK accompanied by IgAN. The type of glomerulonephritis complicated with TAK differs among regions, and patients with TAK are more likely to experience IgAN than the healthy population.

  75. 播種性クリプトコッカス症発症後に血球貪食症候群を呈したループス腎患者の一例

    成田 衛, 丹野 唯人, 秋田 佳奈恵, 星 陽介, 佐藤 紘子, 白井 剛志, 藤井 博司, 石井 智徳

    日本リウマチ学会北海道・東北支部学術集会抄録集　31回　49-49　2022年1月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  76. 全身性エリテマトーデスに合併した後天性第XI因子欠乏症の帝王切開に際して血漿交換を施行した1例

    丹野 唯人, 石井 智徳, 成田 衛, 星 陽介, 秋田 佳奈恵, 町山 智章, 佐藤 紘子, 白井 剛志, 藤井 博司, 張替 俊郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　31回　52-52　2022年1月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  77. 巨細胞性動脈炎に対するトシリズマブ導入後にサルモネラ敗血症を来した1例

    星 陽介, 成田 衛, 丹野 唯人, 秋田 佳奈恵, 佐藤 紘子, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　31回　54-54　2022年1月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  78. エタネルセプト開始後に抗MDA5抗体陽性皮膚筋炎を発症した関節リウマチの一例

    岡崎 創司, 白井 剛志, 高橋 幹弘, 石井 悠翔, 秋田 佳奈恵, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　31回　45-45　2022年1月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  79. エタネルセプト開始後に抗MDA5抗体陽性皮膚筋炎を発症した関節リウマチの一例

    岡崎 創司, 白井 剛志, 高橋 幹弘, 石井 悠翔, 秋田 佳奈恵, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　31回　45-45　2022年1月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  80. 巨細胞性動脈炎に対するトシリズマブ導入後にサルモネラ敗血症を来した1例

    星 陽介, 成田 衛, 丹野 唯人, 秋田 佳奈恵, 佐藤 紘子, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　31回　54-54　2022年1月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  81. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review. 国際誌

    Tomoyuki Mutoh, Tsuyoshi Shirai, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    Rheumatology international　42　(11)　2069-2076　2021年7月21日

    DOI： 10.1007/s00296-021-04950-z 　

    詳細を見る 詳細を閉じる

    Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic autoimmune disorder classified under anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, predominantly affecting small- to medium-sized vessels, characterized by asthma, eosinophilia, and necrotizing granulomatous inflammation. Most patients with EGPA experience peripheral neuropathy, whereas intracerebral hemorrhage is rare as EGPA-related presentation in central nervous system involvement, causing severe morbidity and mortality. Here, we present a 45-year-old man with refractory EGPA who developed intracerebral hemorrhage as the first manifestation, followed by cardiac involvement. This patient with a history of bronchial asthma developed a right putaminal hemorrhage caused by EGPA. Although intravenous cyclophosphamide (IVCY) and mepolizumab (MPZ) induced remission, relapse was frequently observed. Subsequently, he developed cardiomyopathy despite administration of rituximab (RTX) substituted from IVCY and MPZ. Combined immunosuppressive therapy, including IVCY, MPZ, and RTX was required to inhibit vascular inflammation, leading to sustained remission. We review previously published literature while focusing on the clinical features of patients with intracerebral hemorrhage caused by EGPA and describe clinical characteristics for detecting EGPA in patients with intracerebral hemorrhage, emphasizing rapid evaluation and recognition of EGPA and adequate intervention in the early vasculitic phase of this disease. We also refer to the immunological aspects of this case. It is important to consider "multi-targeted therapy" through interleukin-5 suppression and B cell depletion in the management of refractory EGPA.

  82. 【ステロイドからの離脱を目指す膠原病診療】高安動脈炎にtocilizumabが保険適用となって、ステロイドの使い方は変わるか?

    白井 剛志, 石井 智徳

    リウマチ科　65　(6)　642-648　2021年6月

    出版者・発行元： (有)科学評論社

    ISSN：0915-227X

  83. Cyclophosphamide-associated enteritis presenting with severe protein-losing enteropathy in granulomatosis with polyangiitis: A case report. 国際誌

    Hiroko Sato, Tsuyoshi Shirai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    World journal of gastroenterology　27　(20)　2657-2663　2021年5月28日

    DOI： 10.3748/wjg.v27.i20.2657 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Although cyclophosphamide (CPA) is the key drug for the treatment of autoimmune diseases including vasculitides, it has some well-known adverse effects, such as myelosuppression, hemorrhagic cystitis, infertility, and infection. However, CPA-associated severe enteritis is a rare adverse effect, and only one case with a lethal clinical course has been reported. Therefore, the appropriate management of patients with CPA-associated severe enteritis is unclear. CASE SUMMARY: We present the case of a 61-year-old woman diagnosed with granulomatosis with polyangiitis based on the presence of symptoms in ear, lung, and, kidney with positive myeloperoxidase-antineutrophil cytoplasmic antibody. She received pulsed methylprednisolone followed by prednisolone 55 mg/d and intravenous CPA at a dose of 500 mg/mo. Ten days after the second course of intravenous CPA, she developed nausea, vomiting, and diarrhea, and was admitted to the hospital. Laboratory testing revealed hypoalbuminemia, suggesting protein-losing enteropathy. Computed tomography revealed wall thickening of the stomach, small intestine, and colon with contrast enhancement on the lumen side. Antibiotics and immunosuppressive therapy were not effective, and the patient's enteritis did not improve for > 4 mo. Because her condition became seriously exhausted, corticosteroids were tapered and supportive therapies including intravenous hyperalimentation, replenishment of albumin and gamma globulin, plasma exchange, and infection control were continued. These supportive therapies improved her condition, and her enteritis gradually regressed. She was finally discharged 7 mo later. CONCLUSION: Immediate discontinuation of CPA and intensive supportive therapy are crucial for the survival of patients with CPA-associated severe enteritis.

  84. CTD関連 非強皮症合併肺動脈性肺高血圧症の臨床

    石井 智徳, 藤井 博司, 白井 剛志, 佐藤 紘子, 星 陽介, 秋田 佳奈恵

    日本肺高血圧・肺循環学会学術集会・日本小児肺循環研究会プログラム・抄録集　6回・27回　17-17　2021年5月

    出版者・発行元： 日本肺高血圧・肺循環学会・日本小児肺循環研究会

  85. Association of various myositis-specific autoantibodies with dermatomyositis and polymyositis triggered by pregnancy. 国際誌

    Chikaho Akiyama, Tsuyoshi Shirai, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    Rheumatology international　42　(7)　1271-1280　2021年4月10日

    DOI： 10.1007/s00296-021-04851-1 　

    詳細を見る 詳細を閉じる

    Although pregnancy is an important risk factor for autoimmune rheumatic diseases, little is known regarding the association between pregnancy and dermatomyositis (DM) or polymyositis (PM). Herein, we present two patients with DM that developed during the perinatal period. The first patient was positive for anti-aminoacyl synthetase (ARS) antibody and developed DM in the 14th week of pregnancy. Despite treatment, her foetus died of intrauterine growth restriction in the 27th week. The second patient was positive for anti-melanoma differentiation-associated gene 5 (MDA-5) antibody and developed DM 1 week after miscarriage at 9 weeks of gestation. The patient developed severe interstitial pneumonia, and intensive therapy including tofacitinib and rituximab administration was required. Our cases and a literature review revealed that various myositis-specific autoantibodies, including anti-ARS, anti-Mi-2, anti-TIF-1γ, and anti-MDA-5, are associated with DM and PM triggered by pregnancy. We also found that delay in commencing treatment in case of active disease including myositis and interstitial pneumonia, and poor response to corticosteroids were related to poor foetal outcomes in DM and PM. Although rare in pregnant women, it is critical to consider the possibility of DM and PM in patients presenting with rash, fever, weakness, and cough, and testing for myositis-specific autoantibodies is recommended.

  86. 血管炎診療の進歩 高安動脈炎における自己抗体の意義

    石井 智徳, 白井 剛志, 武藤 智之, 藤井 博司, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　65回　183-183　2021年3月

    出版者・発行元： (一社)日本リウマチ学会

  87. Cutting-edge knowledge on pathogenic autoantibodies and immune tolerance SARFによる高安動脈炎の新規自己抗原の同定とその病的意義について

    藤井 博司, 白井 剛志, 武藤 智之, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　65回　229-229　2021年3月

    出版者・発行元： (一社)日本リウマチ学会

  88. 多発性筋炎・皮膚筋炎:治療 抗MDA5抗体陽性皮膚筋炎に伴う急速進行性間質性肺炎に対するトファシチニブ、血漿交換、リツキシマブを併用した高強度寛解導入療法の有効性

    白井 剛志, 丹野 唯人, 高橋 美岐, 岡崎 創司, 星 陽介, 町山 智章, 秋田 佳奈恵, 佐藤 紘子, 藤井 博司, 石井 智徳

    日本リウマチ学会総会・学術集会プログラム・抄録集　65回　390-390　2021年3月

    出版者・発行元： (一社)日本リウマチ学会

  89. ベーチェット病 ベーチェット病における血管病変の特徴と再燃に関連する因子の検討

    佐藤 紘子, 丹野 唯人, 高橋 美岐, 岡崎 創司, 星 陽介, 町山 智章, 秋田 佳奈恵, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　65回　425-425　2021年3月

    出版者・発行元： (一社)日本リウマチ学会

  90. リウマチ性疾患の合併症 当院の関節リウマチ患者におけるMTX関連リンパ増殖性疾患40例の診断契機に関する検討

    高橋 美岐, 丹野 唯人, 岡崎 創司, 町山 智章, 星 陽介, 秋田 佳奈恵, 佐藤 紘子, 白井 剛志, 石井 智徳, 藤井 博司, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　65回　4.37-4.37　2021年3月

    出版者・発行元： (一社)日本リウマチ学会

  91. 当科における関節リウマチに対するゴリムマブの長期継続率の検討

    武藤 智之, 永井 泰地, 佐藤 紘子, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　65回　569-569　2021年3月

    出版者・発行元： (一社)日本リウマチ学会

  92. 腹部大動脈周囲炎を合併した好酸球性多発血管炎性肉芽腫症の一例

    秋田 佳奈恵, 藤井 博司, 丹野 唯人, 高橋 美岐, 岡崎 創司, 星 陽介, 佐藤 紘子, 白井 剛志, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　65回　662-662　2021年3月

    出版者・発行元： (一社)日本リウマチ学会

  93. 再燃を繰り返した治療抵抗性好酸球性多発血管炎性肉芽腫症に対してシクロホスファミド、リツキシマブ、メポリズマブ併用療法が有効であった1例

    武藤 智之, 白井 剛志, 永井 泰地, 佐藤 紘子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　65回　663-663　2021年3月

    出版者・発行元： (一社)日本リウマチ学会

  94. 妊娠に関連し発症した抗ARS抗体陽性と抗MDA5抗体陽性皮膚筋炎の2例

    秋山 悠歩, 白井 剛志, 佐藤 紘子, 高橋 幹弘, 丹野 唯人, 高橋 美岐, 岡崎 創司, 星 陽介, 秋田 佳奈恵, 藤井 博司, 石井 智徳

    日本リウマチ学会総会・学術集会プログラム・抄録集　65回　725-725　2021年3月

    出版者・発行元： (一社)日本リウマチ学会

  95. シクロホスファミドとアザチオプリンによる寛解維持が困難でインフリキシマブが有効であった再発性多発軟骨炎の一例

    秋田 佳奈恵, 白井 剛志, 丹野 唯人, 高橋 美岐, 岡崎 創司, 星 陽介, 佐藤 紘子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　30回　41-41　2021年2月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  96. トシリズマブ、サリルマブで加療を行ったTAFRO症候群の一例

    丹野 唯人, 高橋 美岐, 岡崎 創司, 星 陽介, 秋田 佳奈恵, 町山 智章, 佐藤 紘子, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　30回　53-53　2021年2月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  97. SLE、Sjogren症候群を伴う肺多発結節影を来した肺MALT lymphomaの一例

    高橋 幹弘, 岡崎 創司, 秋田 佳奈恵, 石井 悠翔, 丹野 唯人, 高橋 美岐, 星 陽介, 白井 剛志, 石井 智宏, 藤井 博司, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　30回　65-65　2021年2月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  98. SLE、Sjogren症候群を伴う肺多発結節影を来した肺MALT lymphomaの一例

    高橋 幹弘, 岡崎 創司, 秋田 佳奈恵, 石井 悠翔, 丹野 唯人, 高橋 美岐, 星 陽介, 白井 剛志, 石井 智宏, 藤井 博司, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　30回　65-65　2021年2月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  99. Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan. 国際誌 査読有り

    Seiya Oba, Tadashi Hosoya, Miki Amamiya, Takahiro Mitsumura, Daisuke Kawata, Hirokazu Sasaki, Mari Kamiya, Akio Yamamoto, Takahiro Ando, Sho Shimada, Tsuyoshi Shirai, Tsukasa Okamoto, Tomoya Tateishi, Akira Endo, Junichi Aiboshi, Nobuyuki Nosaka, Hideo Yamanouchi, Toyomu Ugawa, Eiki Nagaoka, Keiji Oi, Susumu Tao, Yasuhiro Maejima, Yukie Tanaka, Kousuke Tanimoto, Hiroaki Takeuchi, Shuji Tohda, Akihiro Hirakawa, Tetsuo Sasano, Hirokuni Arai, Yasuhiro Otomo, Yasunari Miyazaki, Shinsuke Yasuda

    Frontiers in cardiovascular medicine　8　767074-767074　2021年

    DOI： 10.3389/fcvm.2021.767074 　

    詳細を見る 詳細を閉じる

    Background: Thrombosis is a characteristic complication in coronavirus disease 2019 (COVID-19). Since coagulopathy has been observed over the entire clinical course, thrombosis might be a clue to understanding the specific pathology in COVID-19. Currently, there is limited epidemiological data of COVID-19-associated thrombosis in the Japanese population and none regarding variant strains of SARS-CoV-2. Here, we elucidate the risk factors and the pattern of thrombosis in COVID-19 patients. Methods: The patients consecutively admitted to Tokyo Medical and Dental University Hospital with COVID-19 were retrospectively analyzed. SARS-CoV-2 variants of concern/interest (VOC/VOI) carrying the spike protein mutants E484K, N501Y, or L452R were identified by PCR-based analysis. All thrombotic events were diagnosed by clinical symptoms, ultrasonography, and/or radiological tests. Results: Among the 516 patients, 32 patients experienced 42 thromboembolic events. Advanced age, severe respiratory conditions, and several abnormal laboratory markers were associated with the development of thrombosis. While thrombotic events occurred in 13% of the patients with a severe respiratory condition, those events still occurred in 2.5% of the patients who did not require oxygen therapy. Elevated D-dimer and ferritin levels on admission were independent risk factors of thrombosis (adjusted odds ratio 9.39 and 3.11, 95% confidence interval 2.08-42.3, and 1.06-9.17, respectively). Of the thrombotic events, 22 were venous, whereas 20 were arterial. While patients with thrombosis received anticoagulation and antiinflammatory therapies with a higher proportion, the mortality rate, organ dysfunctions, and bleeding complications in these patients were higher than those without thrombosis. The incidence of thrombosis in COVID-19 became less frequent over time, such as during the replacement of the earlier strains of SARS-CoV-2 by VOC/VOI and during increased use of anticoagulatory therapeutics. Conclusion: This study elucidated that elevated D-dimer and ferritin levels are useful biomarkers of thrombosis in COVID-19 patients. The comparable incidence of arterial thrombosis with venous thrombosis and the development of thrombosis in less severe patients required further considerations for the management of Japanese patients with COVID-19. Further studies would be required to identify high-risk populations and establish appropriate interventions for thrombotic complications in COVID-19.

  100. The feasible maintenance dose of corticosteroid in Takayasu arteritis in the era of biologic therapy

    T. Shirai, H. Sato, H. Fujii, T. Ishii, H. Harigae

    Scandinavian Journal of Rheumatology　50　(6)　462-468　2021年

    出版者・発行元： Taylor and Francis Ltd.

    DOI： 10.1080/03009742.2021.1881155 　

    ISSN：1502-7732 0300-9742

  101. 【リウマチ性疾患のリスク因子・予後予測因子】大型血管炎の予後予測因子と寛解維持

    白井 剛志, 石井 智徳

    リウマチ科　64　(4)　461-468　2020年10月

    出版者・発行元： (有)科学評論社

    ISSN：0915-227X

  102. Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus.

    Satoshi Ichikawa, Noriko Fukuhara, Tsuyoshi Shirai, Tomonori Ishii, Ryo Ichinohasama, Hideo Harigae

    International journal of hematology　112　(4)　592-596　2020年10月

    DOI： 10.1007/s12185-020-02914-w 　

    詳細を見る 詳細を閉じる

    Increased incidence of lymphoproliferative disorders is reported in patients with autoimmune diseases, majority of which have a B-cell phenotype and are pathogenetically associated with the reactivation of Epstein-Barr virus (EBV). However, EBV-associated T/NK-cell lymphoma has hardly been reported. We present the case of a 68-year-old-woman, who had been diagnosed with systemic lupus erythematosus (SLE) 28 years back and was treated with various immunosuppressive agents including steroids, cyclophosphamide, and tacrolimus. She presented with a progressively worsening swelling of the right thigh for the last few months. Radiological examination revealed an intramuscular bulky tumor without any other lesions and the biopsy results led to a diagnosis of extranodal NK/T-cell lymphoma, nasal type (ENKL). Concurrent chemoradiotherapy resulted in a complete response, which has been sustained for more than 2 years without requiring additional therapy. After the initiation of chemotherapy, SLE did not worsen with the administration of low-dose corticosteroids. To the best of our knowledge, this is the first case report of a localized extranasal ENKL developing in a patient with SLE.

  103. 全身性結合織疾患の難治性病態 SLEに合併したADAMTS13インヒビター陰性二次性血栓性血小板減少性紫斑病の一例

    佐藤 紘子, 永井 泰地, 武藤 智之, 町山 智章, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　64回　390-390　2020年8月

    出版者・発行元： (一社)日本リウマチ学会

  104. 大型血管炎 大型血管炎におけるステロイド寛解維持量の検討

    白井 剛志, 佐藤 紘子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　64回　451-451　2020年8月

    出版者・発行元： (一社)日本リウマチ学会

  105. 中小型血管炎(ANCA関連血管炎) 多発血管炎性肉芽腫症における臓器別にみた治療反応性についての検討

    城田 祐子, 白井 剛志, 藤井 博司, 佐藤 紘子, 町山 智章, 堤 智美, 武田 朋樹, 岡 友美子, 小寺 隆雄, 桑田 亮, 石井 智徳, 張替 秀郎, 亀岡 淳一

    日本リウマチ学会総会・学術集会プログラム・抄録集　64回　511-511　2020年8月

    出版者・発行元： (一社)日本リウマチ学会

  106. 中小型血管炎(ANCA関連血管炎) 多発血管炎性肉芽腫症における臓器別にみた治療反応性についての検討

    城田 祐子, 白井 剛志, 藤井 博司, 佐藤 紘子, 町山 智章, 堤 智美, 武田 朋樹, 岡 友美子, 小寺 隆雄, 桑田 亮, 石井 智徳, 張替 秀郎, 亀岡 淳一

    日本リウマチ学会総会・学術集会プログラム・抄録集　64回　511-511　2020年8月

    出版者・発行元： (一社)日本リウマチ学会

  107. Rheumatoid Arthritis After Cord Blood Cell Transplantation. 国際誌 査読有り

    Tsuyoshi Shirai, Yu Mori, Takuya Izumiyama, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases　27　(7)　e276-e277　2020年6月12日

    DOI： 10.1097/RHU.0000000000001430 　

  108. Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. 査読有り

    Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Koichi Onodera, Tsuyoshi Shirai, Yasushi Onishi, Hisayuki Yokoyama, Hiroshi Fujii, Ryo Ichinohasama, Hideo Harigae

    International journal of hematology　111　(5)　667-672　2020年5月

    DOI： 10.1007/s12185-020-02822-z 　

    詳細を見る 詳細を閉じる

    Methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) is unlikely to regress following discontinuation of MTX, and its treatment usually requires chemotherapy. Standard chemotherapy for CHL is the ABVD regimen, which contains pneumotoxic bleomycin. This can be problematic in MTX-CHL patients suffering from an autoimmune disease (AID), such as rheumatoid arthritis (RA), as they frequently have pulmonary complications. However, brentuximab vedotin (BV)-containing chemotherapy without bleomycin (A + AVD regimen) was recently reported to show favorable efficacy for CHL, and could therefore be beneficial in MTX-CHL. We treated three cases of MTX-CHL using the A + AVD regimen. All were female and had received MTX for more than 15 years. Underlying AIDs in these patients were RA in two patients, and overlap syndrome with systemic lupus erythematosus and dermatomyositis in one patient. The A + AVD regimen resulted in a complete response in all patients. Peripheral neuropathy developed in two patients, necessitating reduction of the BV dose. All three patients experienced hematological toxicity necessitating dose reduction; however, no severe adverse effects, including infection or pulmonary complication, were documented. RA was well-controlled without additional immunosuppressants. The A + AVD regimen is a promising chemotherapy for MTX-CHL with favorable efficacy and tolerable toxicity profiles.

  109. Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody 査読有り

    Yusho Ishii, Hiroshi Fujii, Koichiro Sugimura, Tsuyoshi Shirai, Yosuke Hoshi, Yoko Fujita, Yuko Shirota, Tomonori Ishii, Hiroaki Shimokawa, Hideo Harigae

    Case Reports in Rheumatology　2020年2月26日

    DOI： 10.1155/2020/1926908 　

  110. Comment on: Aortarctia: a rare manifestation of relapsing polychondrits 査読有り

    Tsuyoshi Shirai, Koji Murakami, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    Rheumatology　2020年2月5日

    出版者・発行元： Oxford University Press ({OUP})

    DOI： 10.1093/rheumatology/keaa019 　

  111. Interferon α Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus. 国際誌

    Kanae Akita, Ken Yasaka, Tsuyoshi Shirai, Tomonori Ishii, Hideo Harigae, Hiroshi Fujii

    Frontiers in immunology　11　498703-498703　2020年

    DOI： 10.3389/fimmu.2020.498703 　

    詳細を見る 詳細を閉じる

    Systemic lupus erythematosus (SLE) is an autoimmune disease. It is characterized by the production of various pathogenic autoantibodies and is suggested to be triggered by increased type I interferon (IFN) signature. Previous studies have identified increased plasmablasts in the peripheral blood of SLE patients. The biological characteristics of SLE plasmablasts remain unknown, and few treatments that target SLE plasmablasts have been applied despite the unique cellular properties of plasmablasts compared with other B cell subsets and plasma cells. We conducted microarray analysis of naïve and memory B cells and plasmablasts (CD38+CD43+ B cells) that were freshly isolated from healthy controls and active SLE (n = 4, each) to clarify the unique biological properties of SLE plasmablasts. The results revealed that all B cell subsets of SLE expressed more type I IFN-stimulated genes. In addition, SLE plasmablasts upregulated the expression of cell cycle-related genes associated with higher FOXM1 and FOXM1-regulated gene expression levels than that in healthy controls. This suggests that a causative relationship exists between type I IFN priming and enhanced proliferative capacity through FOXM1. The effects of pretreatment of IFNα on B cell activation and FOXM1 inhibitor FDI-6 on B cell proliferation and survival were investigated. Pretreatment with IFNα promoted B cell activation after stimulation with anti-IgG/IgM antibody. Flow cytometry revealed that pretreatment with IFNα preferentially enhanced the Atk and p38 pathways after triggering B cell receptors. FDI-6 inhibited cell division and induced apoptosis in activated B cells. These effects were pronounced in activated B cells pretreated with interferon α. This study can provide better understanding of the pathogenic mechanism of interferon-stimulated genes on SLE B cells and an insight into the development of novel therapeutic strategies.

  112. Migratory Aortitis Associated with Granulocyte-colony-stimulating Factor

    Tsuyoshi Shirai, Hiroka Komatsu, Hiroko Sato, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    INTERNAL MEDICINE　59　(12)　1559-1563　2020年

    DOI： 10.2169/internalmedicine.4331-19 　

    ISSN：0918-2918

    eISSN：1349-7235

  113. Protein-losing gastroenteropathy with severe hypoalbuminemia associated with Sjögren's syndrome: A case report and review of the literature. 査読有り

    Tetsuya Akaishi, Ken Yasaka, Michiaki Abe, Hiroshi Fujii, Mika Watanabe, Tsuyoshi Shirai, Kota Ishizawa, Shin Takayama, Yutaka Kagaya, Hideo Harigae, Tadashi Ishii

    Journal of general and family medicine　21　(1)　24-28　2020年1月

    DOI： 10.1002/jgf2.281 　

    詳細を見る 詳細を閉じる

    A 30-year-old man with severe hypoalbuminemia (serum albumin: 0.9 g/dL) was admitted with severe bilateral leg edema and unilateral pleural effusion. Serum anti-SS-A and SS-B antibody levels were abnormally elevated, and his symptoms fulfilled the diagnostic criteria for Sjögren's syndrome. Technetium-99m albumin scintigraphy revealed protein leakage from a large area of the small intestine. Immunohistochemistry revealed perivascular deposition of C1q, C3d, and immunoglobulin G in the duodenal mucosa. The patient was diagnosed with protein-losing gastroenteropathy associated with Sjögren's syndrome. Within 2 months of treatment with oral prednisolone and mycophenolate mofetil, the clinical symptoms of hypoalbuminemia and Sjögren's syndrome disappeared completely.

  114. Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis

    Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori Ishii, Yuko Shirota, Hideo Harigae, Hiroshi Fujii

    ARTHRITIS & RHEUMATOLOGY　71　2019年10月

    ISSN：2326-5191

    eISSN：2326-5205

  115. Refractory Takayasu arteritis successfully treated with rituximab: case-based review. 国際誌 査読有り

    Mutoh T, Ishii T, Shirai T, Akita K, Kamogawa Y, Fujita Y, Sato H, Shirota Y, Fujii H, Harigae H

    Rheumatology international　39　(11)　1989-1994　2019年8月

    DOI： 10.1007/s00296-019-04390-w 　

    詳細を見る 詳細を閉じる

    Takayasu arteritis (TAK) is a subtype of the large-vessel vasculitis, affecting the aorta and its major branches. Although T cell-mediated autoimmunity is mainly involved in vascular inflammation, in recent years, accumulating evidence suggests the important role of B cells in the pathogenesis and effectiveness of B-cell-targeted therapy with rituximab (RTX), a chimeric anti-CD20 monoclonal antibody in refractory TAK. Herein, we report for the first time a case involving a 34-year-old man with TAK who was refractory to four different biologic agents, such as one selective T-cell co-stimulation modulator (abatacept), one anti-interleukin-6 receptor monoclonal antibody (tocilizumab), and two tumor necrosis factor-α inhibitors (infliximab and etanercept), but eventually achieved remission with RTX. He received a total of six courses of RTX, and doses of prednisolone and methotrexate were tapered without relapse. The current case provided further evidence to the potential role of RTX therapy in patients with refractory TAK, and its efficacy needs to be validated in a controlled trial.

  116. Insufficient use of corticosteroids without immunosuppressants results in higher relapse in Takayasu arteritis. 国際誌 査読有り

    Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H

    The Journal of rheumatology　47　(2)　255-263　2019年5月

    DOI： 10.3899/jrheum.181219 　

    詳細を見る 詳細を閉じる

    OBJECTIVE:Although prednisolone (PSL) and immunosuppressants are key drugs for Takayasu arteritis (TAK) treatment, there is limited evidence on the optimal PSL dose. The aim of this study was to investigate the correlation between the initial PSL dose and relapse in TAK. METHODS:We enrolled 105 patients with TAK who satisfied the criteria of the Japanese Circulation Society and American College of Rheumatology from 1990 to 2015. The clinical characteristics and outcomes of patients with TAK were retrospectively evaluated. The relapse-free period was assessed according to the difference in initial treatments. RESULTS:Relapse was observed in 57 (59.4%) of 96 patients treated with immunosuppressive therapy at diagnosis during a median follow-up of 56 months. Male sex and younger age of onset were significantly associated with relapse. Although ≤30-mg/day PSL monotherapy was preferably prescribed for patients with lower inflammatory markers, compared with &gt;30 mg/day (87.2% vs. 52.6%), a significantly higher relapse rate was observed in the ≤30-mg/day group (hazard ratio, 1.78, P = 0.047). Furthermore, the relapse-free period was longer in patients treated with ≥50-mg/day PSL compared with those treated with ≤40-mg/day PSL. Combination therapy improved the relapse-free period compared with PSL monotherapy in the short term. The initial PSL dose was not associated with adverse events. CONCLUSION:A higher dose of PSL was associated with a significant decrease in the relapse rate. The effect of combination therapy on relapse needs to be further investigated. Lower-dose PSL monotherapy is an undesirable strategy for remission induction in TAK, despite low disease activity.

  117. Muehrcke lines on fingers and toenails. 国際誌 査読有り

    European journal of dermatology : EJD　29　(1)　87-88　2019年2月

    DOI： 10.1684/ejd.2018.3439 　

  118. Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries. 査読有り

    Tsuyoshi Shirai

    Scandinavian journal of rheumatology　48　(4)　308-314　2019年1月23日

    DOI： 10.1080/03009742.2018.1551965 　

    詳細を見る 詳細を閉じる

    OBJECTIVE:Within the spectrum of polyarteritis nodosa (PAN), cutaneous PAN (cPAN) is further classified into mild cPAN and severe cPAN which presents with ulcers, necrosis, or neuritis. As distinguishing between severe cPAN and systemic PAN can be difficult, this study evaluated the clinical characteristics of patients with necrotizing arteritis of medium-sized arteries. METHODS:Forty-one patients diagnosed with necrotizing arteritis of medium-sized arteries between 2008 and 2017 at our institution were enrolled in this study. Clinical background, laboratory findings, treatments, and rates of relapse and death were evaluated. RESULTS:Thirty-six patients were classified as having cPAN (mild, 15; ulcer, nine; neuritis, eight; both, four), and five cases manifested systemic vasculitis. Clinical characteristics of mild cPAN included female predominance (84.6%) and younger age (median 31 years); those of systemic PAN included older age (median 71 years) and higher levels of inflammatory markers. Severe cPAN manifested with intermediate phenotypes. The median doses of prednisolone used to treat mild cPAN, severe cPAN, and systemic PAN were 20.0, 40.0, and 40.0 mg/day, respectively. Immunosuppressants were used in 20.0% of mild cPAN, 90.5% of severe cPAN, and 80.0% of systemic PAN patients. Although the mortality rates were indistinguishable, the relapse rates of severe cPAN (ulcer type) were significantly higher than those of other types (88.9%). CONCLUSION:The clinical characteristics of mild cPAN, severe cPAN (ulcer type), severe cPAN (neuritis type), and systemic PAN were distinct from each other. In particular, patients with severe cPAN (ulcer type) had higher relapse rates, indicating the importance of combination therapy.

  119. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. 国際誌 査読有り

    Tomonori Ishii, Yoshiya Tanaka, Atsushi Kawakami, Kazuyoshi Saito, Kunihiro Ichinose, Hiroshi Fujii, Yuko Shirota, Tsuyoshi Shirai, Yoko Fujita, Ryu Watanabe, Shih-Wei Chiu, Takuhiro Yamaguchi, Hideo Harigae

    Modern rheumatology　28　(6)　986-992　2018年11月

    DOI： 10.1080/14397595.2018.1432331 　

    詳細を見る 詳細を閉じる

    OBJECTIVES: The objective of this study is to evaluate the efficacy and safety of bortezomib for treating systemic lupus erythematosus (SLE), in patients whose disease activity could not be controlled. METHODS: Fourteen SLE patients with persistent disease activity were selected, who required prednisolone doses of >10 mg/d despite concomitant immunosuppressive therapy. Patients were randomly administered either bortezomib or a placebo, eight times. The primary and secondary end-points were a change in anti-dsDNA antibody titer at week 24 and the SLE Responder Index (SRI), respectively. RESULTS: In the bortezomib group, four out of eight patients discontinued the trial; three others failed to complete the minimum protocol treatment due to adverse reactions. The changes in anti-dsDNA antibody titers at week 24 were 4.24% and -1.96%, for the bortezomib and placebo groups, respectively, disconfirming bortezomib's efficacy. In contrast, the corresponding SRI at week 12 was 75% and 40%. CONCLUSIONS: As bortezomib therapy for SLE is associated with many adverse reactions, treatment indications should be selected carefully, and protocols should aim to prevent these occurrences. Although the change in anti-dsDNA antibody titer did not support the efficacy of bortezomib as a treatment for SLE, high SRI in the treatment group suggests bortezomib may utilize mechanisms other than inhibition of anti-dsDNA antibody production.

  120. 【わかりやすいANCA関連血管炎性中耳炎(OMAAV)-早期診断と治療-】全身疾患におけるANCA測定の意義 査読有り

    白井 剛志, 石井 智徳

    ENTONI　(217)　17-22　2018年4月

    出版者・発行元： (株)全日本病院出版会

    ISSN：1346-2067

  121. Immunosuppressive therapy ameliorates refractory vasospastic angina, severe pulmonary hypertension, and bronchiolitis in a patient with eosinophilic granulomatosis with polyangiitis: a case report 査読有り

    Ryo Konno, Shunsuke Tatebe, Tsuyoshi Shirai, Hiroaki Shimokawa

    European Heart Journal - Case Reports　2　(2)　1-5　2018年4月

    出版者・発行元： Oxford University Press ({OUP})

    DOI： 10.1093/ehjcr/yty050 　

    ISSN：2514-2119

  122. Nasal Septal Perforation in Propylthiouracil-Induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 国際誌 査読有り

    Yusho Ishii, Tsuyoshi Shirai, Yousuke Hoshi, Yoko Fujita, Yuko Shirota, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    Case Reports in Rheumatology　2018　1-8192021　2018年

    出版者・発行元： Hindawi Limited

    DOI： 10.1155/2018/8192021 　

  123. Takayasu arteritis coexisting with sclerosing osteomyelitis 査読有り

    Tsuyoshi Shirai, Riiza Hanaoka, Yusuke Goto, Ikuho Kojima, Yusho Ishii, Yousuke Hoshi, Yoko Fujita, Yuko Shirota, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    Internal Medicine　57　(13)　1929-1934　2018年

    DOI： 10.2169/internalmedicine.0329-17 　

    ISSN：0918-2918

    eISSN：1349-7235

  124. Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) restricted to the limbs 査読有り

    Yoshie Ojima, Kinya Sawada, Hiroshi Fujii, Tsuyoshi Shirai, Ayako Saito, Saeko Kagaya, Satoshi Aoki, Yoichi Takeuchi, Tomonori Ishii, Tasuku Nagasawa

    Internal Medicine　57　(9)　1301-1308　2018年

    出版者・発行元： Japanese Society of Internal Medicine

    DOI： 10.2169/internalmedicine.9848-17 　

    ISSN：1349-7235 0918-2918

  125. Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity 査読有り

    Tomoko Ikeda, Hiroshi Fujii, Masato Nose, Yukiko Kamogawa, Tsuyoshi Shirai, Yuko Shirota, Tomonori Ishii, Hideo Harigae

    Arthritis Research & Therapy　19　(1)　2017年8月11日

    出版者・発行元： Springer Nature

    DOI： 10.1186/s13075-017-1397-7 　

    ISSN：1478-6362

  126. Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity 査読有り

    Tomoko Ikeda, Hiroshi Fujii, Masato Nose, Yukiko Kamogawa, Tsuyoshi Shirai, Yuko Shirota, Tomonori Ishii, Hideo Harigae

    ARTHRITIS RESEARCH & THERAPY　19　(1)　187　2017年8月

    DOI： 10.1186/s13075-017-1397-7 　

    ISSN：1478-6354

    eISSN：1478-6362

  127. リウマチ性疾患の合併症 11C-BF-227-PETによる全身アミロイド計測を試みたアミロイドーシス6症例の検討

    城田 祐子, 石井 悠翔, 星 陽介, 藤田 洋子, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　61回　585-585　2017年3月

    出版者・発行元： (一社)日本リウマチ学会

  128. 心臓MRIで遅延造影なく心臓生検で心筋炎の診断がついた全身性エリテマトーデス(SLE)の一例

    藤田 洋子, 星 陽介, 石井 悠翔, 武藤 智之, 町山 智章, 秋田 佳奈恵, 鴨川 由起子, 白井 剛志, 城田 祐子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　61回　674-674　2017年3月

    出版者・発行元： (一社)日本リウマチ学会

  129. 免疫抑療法制が奏効した抗セントリオール抗体陽性全身性強皮症関連肺動脈性肺高血圧症の1例

    石井 悠翔, 藤田 洋子, 白井 剛志, 城田 祐子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　61回　748-748　2017年3月

    出版者・発行元： (一社)日本リウマチ学会

  130. Relapsing Polychondritis Complicated by Myelodysplastic Syndrome Is Resistant to Immunosuppression: Comment on the Article by Dion et al 査読有り

    Tsuyoshi Shirai, Hiroshi Fujii, Ryoko Saito, Kentaro Nasu, Yukiko Kamogawa, Noriko Fukuhara, Yoko Fujita, Yuko Shirota, Tomonori Ishii, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　69　(3)　682-683　2017年3月

    DOI： 10.1002/art.39969 　

    ISSN：2326-5191

    eISSN：2326-5205

  131. Extracorporeal Shock Wave Therapy for Digital Ulcers of Systemic Sclerosis: A Phase 2 Pilot Study 査読有り

    Shinichiro Saito, Tomonori Ishii, Yukiko Kamogawa, Ryu Watanabe, Tsuyoshi Shirai, Yoko Fujita, Yuko Shirota, Hiroshi Fujii, Kenta Ito, Hiroaki Shimokawa, Takuhiro Yamaguchi, Yasushi Kawaguchi, Hideo Harigae

    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　238　(1)　39-47　2016年1月

    DOI： 10.1620/tjem.238.39 　

    ISSN：0040-8727

    eISSN：1349-3329

  132. Macrophages in vascular inflammation - From atherosclerosis to vasculitis 査読有り

    Tsuyoshi Shirai, Marc Hilhorst, David G. Harrison, Joerg J. Goronzy, Cornelia M. Weyand

    AUTOIMMUNITY　48　(3)　139-151　2015年5月

    DOI： 10.3109/08916934.2015.1027815 　

    ISSN：0891-6934

    eISSN：1607-842X

  133. Chronic Lupus Peritonitis Is Characterized by the Ascites with a Large Content of Interleukin-6 査読有り

    Ryu Watanabe, Hiroshi Fujii, Yukiko Kamogawa, Kyohei Nakamura, Tsuyoshi Shirai, Tomonori Ishii, Hideo Harigae

    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　235　(4)　289-294　2015年4月

    DOI： 10.1620/tjem.235.289 　

    ISSN：0040-8727

    eISSN：1349-3329

  134. Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions 査読有り

    Hong, J., Maron, D.J., Shirai, T., Weyand, C.M.

    International Journal of Clinical Rheumatology　10　(5)　365-381　2015年

    DOI： 10.2217/ijr.15.33 　

  135. T cell-macrophage interactions and granuloma formation in vasculitis 査読有り

    Marc Hilhorst, Tsuyoshi Shirai, Gerald Berry, Joerg J. Goronzy, Cornelia M. Weyand

    FRONTIERS IN IMMUNOLOGY　5　(SEP)　1-14　2014年9月

    DOI： 10.3389/fimmu.2014.00432 　

    ISSN：1664-3224

  136. Autophagy plays a protective role as an anti-oxidant system in human T cells and represents a novel strategy for induction of T-cell apoptosis 査読有り

    Ryu Watanabe, Hiroshi Fujii, Tsuyoshi Shirai, Shinichiro Saito, Tomonori Ishii, Hideo Harigae

    EUROPEAN JOURNAL OF IMMUNOLOGY　44　(8)　2508-2520　2014年8月

    DOI： 10.1002/eji.201344248 　

    ISSN：0014-2980

    eISSN：1521-4141

  137. Ulcerative colitis is not a rare complication of Takayasu arteritis 査読有り

    Ryu Watanabe, Tomonori Ishii, Kyohei Nakamura, Tsuyoshi Shirai, Hiroshi Fujii, Shinichiro Saito, Hideo Harigae

    MODERN RHEUMATOLOGY　24　(2)　372-373　2014年3月

    DOI： 10.3109/14397595.2013.854045 　

    ISSN：1439-7595

    eISSN：1439-7609

  138. Successful Use of Intensive Immunosuppressive Therapy for Treating Simultaneously Occurring Cerebral Lesions and Pulmonary Arterial Hypertension in a Patient with Systemic Lupus Erythematosus 査読有り

    Ryu Watanabe, Hiroshi Fujii, Tsuyoshi Shirai, Shinichiro Saito, Akira Hatakeyama, Koichiro Sugimura, Yoshihiro Fukumoto, Tomonori Ishii, Hideo Harigae

    INTERNAL MEDICINE　53　(6)　627-631　2014年

    DOI： 10.2169/internalmedicine.53.0514 　

    ISSN：0918-2918

    eISSN：1349-7235

  139. Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy 査読有り

    Ryu Watanabe, Tomonori Ishii, Kyohei Nakamura, Tsuyoshi Shirai, Yumi Tajima, Hiroshi Fujii, Hideo Harigae

    MODERN RHEUMATOLOGY　23　(6)　1094-1100　2013年11月

    DOI： 10.1007/s10165-012-0797-4 　

    ISSN：1439-7595

    eISSN：1439-7609

  140. Polyarteritis nodosa clinically mimicking nonocclusive mesenteric ischemia 査読有り

    Tsuyoshi Shirai, Hiroshi Fujii, Shinichiro Saito, Tomonori Ishii, Hideyuki Yamaya, Shigehito Miyagi, Satoshi Sekiguchi, Naoki Kawagishi, Masato Nose, Hideo Harigae

    WORLD JOURNAL OF GASTROENTEROLOGY　19　(23)　3693-3698　2013年6月

    DOI： 10.3748/wjg.v19.i23.3693 　

    ISSN：1007-9327

  141. 【血管炎-基礎と臨床のクロストーク-】 最新の研究トピックス AP-VAS 2012から 血管炎の基礎研究 血管内皮細胞表面に対する抗FLRT2自己抗体 査読有り

    白井 剛志, 藤井, 博司, 小野, 栄夫, 石井, 智徳, 張替 秀郎

    日本臨床　71　(増刊1 血管炎)　497-501　2013年2月

  142. 自己抗体 顕著な脳炎を呈した中枢神経ループス患者における新規抗EphB2自己抗体の同定 査読有り

    白井剛志, 藤井博司, 中村恭平, 渡部龍, 田島結実, 高澤徳彦, 石井智徳, 張替秀郎

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　56回・21回　452-452　2012年3月

  143. 腎機能障害と血小板減少を呈し、レボレード投与、エンドキサンパルス療法が奏功した強皮症の一例 査読有り

    佐々木結実, 中村恭平, 渡部龍, 白井剛志, 藤井博司, 高澤徳彦, 石井智徳, 張替秀郎

    日本リウマチ学会総会学術集会国際リウマチシンポジウムプログラム抄録集56回・21回　663　2012年3月

  144. 血管炎に合併した肥厚性硬膜炎の３例 査読有り

    中村恭平, 渡部龍, 白井剛志, 田島結実, 藤井博司, 高澤徳彦, 石井智徳, 張替秀郎

    日本リウマチ学会総会学術集会国際リウマチシンポジウムプログラム抄録集56回・21回　615　2012年3月

  145. ANCA関連血管炎が疑われた非結核性抗酸菌症と考えられる１例 査読有り

    高澤徳彦, 中村恭平, 渡部龍, 白井剛志, 佐々木結実, 藤井博司, 石井智徳, 張替秀郎

    日本リウマチ学会総会学術集会国際リウマチシンポジウムプログラム抄録集56回・21回　543　2012年3月

  146. 大量ガンマグロブリン療法が奏功した視神経周囲炎を伴うChurg-Strauss症候群の一例 査読有り

    渡部龍, 石井智徳, 中村恭平, 白井剛志, 田島結実, 藤井博司, 高澤徳彦, 張替秀郎

    末梢神経　22　(2)　264-265　2011年12月

    ISSN：0917-6772

  147. リコンビナント抗原を使用したELISA法によるANCA測定キット(コスミック社)の基礎的・臨床的検討 査読有り

    白井剛志, 石井智徳, 中村恭平, 渡部龍, 田島結実, 藤井博司, 高澤徳彦, 張替秀郎

    医学と薬学　65　(4)　517-523　2011年4月

  148. Thrombotic Microangiopathy Presenting with a Considerable Accumulation of Ascites: A Case Report 査読有り

    Tsuyoshi Shirai, Tomonori Ishii, Ryu Watanabe, Yumi Tajima, Hiroshi Fujii, Naruhiko Takasawa, Hiroshi Sato, Hideo Harigae

    INTERNAL MEDICINE　50　(1)　53-57　2011年

    DOI： 10.2169/internalmedicine.50.4330 　

    ISSN：0918-2918

  149. The use of tacrolimus for recurrent lupus enteritis: a case report. 国際誌 査読有り

    Tsuyoshi Shirai, Yasuhiko Hirabayashi, Ryu Watanabe, Yumi Tajima, Hiroshi Fujii, Naruhiko Takasawa, Tomonori Ishii, Hideo Harigae

    Journal of medical case reports　4　150-150　2010年5月24日

    DOI： 10.1186/1752-1947-4-150 　

  150. 多量腹水、下腿浮腫、血小板減少を呈した血栓性微小血管障害症(TMA)の一例 査読有り

    白井剛志, 渡部龍, 田島結実, 藤井博司, 高澤徳彦, 石井智徳, 張替秀郎

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　54回・19回　612-612　2010年3月

  151. Pregnancy-Associated Thrombotic Thrombocytopenic Purpura with Anti-Centromere Antibody-Positive Raynaud's Syndrome 査読有り

    Ryu Watanabe, Tsuyoshi Shirai, Yumi Tajima, Hiroto Ohguchi, Yasushi Onishi, Hiroshi Fujii, Naruhiko Takasawa, Tomonori Ishii, Hideo Harigae

    INTERNAL MEDICINE　49　(12)　1229-1232　2010年

    DOI： 10.2169/internalmedicine.49.3465 　

    ISSN：0918-2918

    eISSN：1349-7235

  152. 眼球突出、PR3-ANCA高値を呈しWegener肉芽腫との鑑別を要したT細胞リンパ腫の一例

    白井 剛志, 田島 結実, 高橋 令子, 藤井 博司, 高澤 徳彦, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　53回・18回　320-320　2009年3月

    出版者・発行元： (一社)日本リウマチ学会

  153. Peripheral T Cell Lymphoma with a High Titer of Proteinase-3-Antineutrophil Cytoplasmic Antibodies that Resembled Wegener&apos;s Granulomatosis 査読有り

    Tsuyoshi Shirai, Reiko Takahashi, Yumi Tajima, Katsura Kohata, Joji Yamamoto, Hiroshi Fujii, Naruhiko Takasawa, Kenichi Ishizawa, Ryo Ichinohasama, Tomonori Ishii, Hideo Harigae

    INTERNAL MEDICINE　48　(23)　2041-2045　2009年

    DOI： 10.2169/internalmedicine.48.2600 　

    ISSN：0918-2918

  154. アンチゲネミア陰性を示した汎血球減少を伴うサイトメガロウイルス感染症の一例

    白井 剛志, 高橋 令子, 平林 泰彦, 石井 智徳, 高澤 徳彦, 田島 結実, 張替 秀郎

    日本臨床免疫学会会誌　31　(4)　335-335　2008年8月

    出版者・発行元： (一社)日本臨床免疫学会

    ISSN：0911-4300

    eISSN：1349-7413

  155. Percutaneous endoscopic cecostomy (PEC) for ileus in aged patients 査読有り

    Uno, Y., Nagaoka, Y., Shirai, T.

    Gastroenterological Endoscopy　50　(3)　408-416　2008年

︎全件表示 ︎最初の5件までを表示

MISC 38

  1. AB1031 PATIENT SATISFACTION OF SUBCUTANEOUS BELIMUMAB AND IMPACT ON DISEASE ACTIVITY AND LUPUS NEPHRITIS IN LONG-LASTING SYSTEMIC LUPUS ERYTHEMATOSUS

    Tsuyoshi Shirai, Maya Yamato, Yusho Ishii, Hiroko Sato, Tomonori Ishii, Hiroshi Fujii

    EULAR Congress 2024　2024年6月10日

    出版者・発行元： BMJ Publishing Group Ltd and European League Against Rheumatism

    DOI： 10.1136/annrheumdis-2024-eular.1599 　

  2. 非典型的な臨床経過と腎病理を呈した多発血管炎性肉芽腫症

    木之村聡介, 豊原敬文, 白井剛志, 秋保真穂, 菊地晃一, 牧野塁, 吉田舞, 大江佑治, 岡本好司, 長澤将, 宮崎真理子, 佐藤博, 藤井博司, 田中哲洋

    日本腎臓学会誌(Web)　66　(6-E)　2024年

    ISSN： 1884-0728

  3. IBD病態を踏まえた今後の治療ストラテジー 抗EPCR抗体価と潰瘍性大腸炎の病態および治療反応性との関連に関する検討

    角田 洋一, 白井 剛志, 正宗 淳

    Gastroenterological Endoscopy　64　(Suppl.2)　2023-2023　2022年10月

    出版者・発行元： (一社)日本消化器内視鏡学会

    ISSN： 0387-1207

    eISSN： 1884-5738

  4. SLE・抗リン脂質抗体症候群(臨床) 我が国の若年全身性エリテマトーデス患者における診断早期のQOL変化に関する検討【日本リウマチ学会妊娠登録調査小委員会 我が国の若年全身性エリテマトーデス患者の現状と妊娠転帰を含む長期・短期予後に関する前向きコホート研究(PLEASURE-J研究)】中間報告

    金子 佳代子, 阿部 靖矢, 岩井 秀之, 岩田 恭宜, 大西 香絵, 岸 崇之, 島田 裕美, 白井 剛志, 土田 優美, 中山田 真吾, 仁科 直, 根本 卓也, 平野 亨, 三浦 瑶子, 森山 繭子, 矢嶋 宣幸, 奥 健志, 竹内 勤, 田中 良哉, 藤尾 圭志, 松下 雅和, 宮前 多佳子, 和田 隆志, 村島 温子

    日本リウマチ学会総会・学術集会プログラム・抄録集　64回　378-378　2020年8月

    出版者・発行元： (一社)日本リウマチ学会

  5. 小児の膠原病および若年性特発性関節炎 我が国の若年全身性エリテマトーデス患者の現状と妊娠転帰を含む長期・短期予後に関する前向きコホート研究【日本リウマチ学会ワーキンググループ】小児発症例中間報告

    宮前 多佳子, 金子 佳代子, 阿部 靖矢, 岩井 秀之, 岩田 恭宜, 大西 香絵, 岸 崇之, 島田 裕美, 白井 剛志, 土田 優美, 中山田 真吾, 仁科 直, 根本 卓也, 平野 亨, 三浦 瑶子, 森山 繭子, 矢嶋 宣幸, 奥 健志, 竹内 勤, 田中 良哉, 藤尾 圭志, 松下 雅和, 和田 隆志, 村島 温子

    日本リウマチ学会総会・学術集会プログラム・抄録集　64回　415-415　2020年8月

    出版者・発行元： (一社)日本リウマチ学会

  6. 重症な急速進行性間質性肺炎を合併した抗MDA5抗体陽性皮膚筋炎に対して多剤併用療法が奏効した一例 査読有り

    町山 智章, 白井 剛志, 藤田 洋子, 鴨川 由紀子, 佐藤 紘子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　29回　74-74　2019年11月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  7. 後部虚血性視神経症による急性視力障害を来たした小型血管炎の1例 査読有り

    李 邱平, 白井 剛志, 永井 泰地, 町山 智章, 鴨川 由起子, 佐藤 紘子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会北海道・東北支部学術集会抄録集　29回　78-78　2019年11月

    出版者・発行元： (一社)日本リウマチ学会-北海道・東北支部

  8. IDENTIFICATION OF ENDOTHELIAL PROTEIN C RECEPTOR AND SCAVENGER RECEPTOR CLASS B TYPE 1 AS MAJOR AUTOANTIGENS IN TAKAYASU ARTERITIS

    Tsuyoshi Shirai, Tomoyuki Mutoh, Tomonori Ishii, Hiroshi Fujii, Hideo Harigae

    ANNALS OF THE RHEUMATIC DISEASES　78　437-438　2019年6月

    DOI： 10.1136/annrheumdis-2019-eular.602 　

    ISSN： 0003-4967

    eISSN： 1468-2060

  9. 血管炎(大型血管炎)-3 生物学的製剤を使用した大型血管炎患者の検討 査読有り

    白井 剛志, 武藤 智之, 藤田 洋子, 藤井 博司, 石井 智徳, 平林 泰彦, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　63回　452-452　2019年3月

    出版者・発行元： (一社)日本リウマチ学会

  10. リウマチ性疾患の合併症-1 膠原病関連肺動脈性肺高血圧症における各種自己抗体別にみた長期予後の違いについての検討 査読有り

    城田 祐子, 白井 剛志, 藤井 博司, 小寺 隆雄, 亀岡 淳一, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　63回　465-465　2019年3月

    出版者・発行元： (一社)日本リウマチ学会

  11. ベーチェット病 血管ベーチェット病の臨床的特徴と治療内容の検討 査読有り

    佐藤 紘子, 星 陽介, 町山 智章, 鴨川 由起子, 藤田 洋子, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　63回　561-561　2019年3月

    出版者・発行元： (一社)日本リウマチ学会

  12. 血管炎(大型血管炎)-3 生物学的製剤を使用した大型血管炎患者の検討

    白井 剛志, 武藤 智之, 藤田 洋子, 藤井 博司, 石井 智徳, 平林 泰彦, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　63回　452-452　2019年3月

    出版者・発行元： (一社)日本リウマチ学会

  13. リウマチ性疾患の合併症-1 膠原病関連肺動脈性肺高血圧症における各種自己抗体別にみた長期予後の違いについての検討

    城田 祐子, 白井 剛志, 藤井 博司, 小寺 隆雄, 亀岡 淳一, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　63回　465-465　2019年3月

    出版者・発行元： (一社)日本リウマチ学会

  14. ベーチェット病 血管ベーチェット病の臨床的特徴と治療内容の検討

    佐藤 紘子, 星 陽介, 町山 智章, 鴨川 由起子, 藤田 洋子, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　63回　561-561　2019年3月

    出版者・発行元： (一社)日本リウマチ学会

  15. High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis

    Tsuyoshi Shirai, Tomoyuki Muto, Yuko Shirota, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　70　2018年9月

    ISSN： 2326-5191

    eISSN： 2326-5205

  16. Autoantibodies and Clinical Outcomes in Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases

    Yuko Shirota, Tomonori Ishii, Tsuyoshi Shirai, Hiroshi Fujii, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　70　2018年9月

    ISSN： 2326-5191

    eISSN： 2326-5205

  17. Comparative Analysis of the Macrophage Glycolytic Machinery in Giant Cell Arteritis (GCA) and in Coronary Artery Disease (CAD)

    Cornelia M. Weyand, Ryu Watanabe, Tsuyoshi Shirai, Hui Zhang, Gerald Berry, Jorg Goronzy

    ARTHRITIS & RHEUMATOLOGY　69　2017年10月

    ISSN： 2326-5191

    eISSN： 2326-5205

  18. Non-Randomized Controlled Trial to Evaluate the Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis

    Tomonori Ishii, Yasushi Kawaguchi, Osamu Ishikawa, Naruhiko Takasaawa, Takao Kodera, Hidekata Yasuoka, Yuichi Takahashi, Osamu Takai, Izaya Nakaya, Hiroshi Fujii, Yukiko Kamogawa, Yuko Shirota, Tsuyoshi Shirai, Yoko Fujita, Shinichiro Saito, Hiroaki Shimokawa, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　69　2017年10月

    ISSN： 2326-5191

    eISSN： 2326-5205

  19. Molecular Mechanism for the Therapeutic Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers of Systemic Sclerosis

    Yukiko Kamogawa, Hiroshi Fujii, Tsuyoshi Shirai, Tomonori Ishii, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　69　2017年10月

    ISSN： 2326-5191

    eISSN： 2326-5205

  20. Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries

    Tsuyoshi Shirai, Hiroshi Fujii, Yoko Fujita, Yuko Shirota, Tomonori Ishii, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　69　2017年10月

    ISSN： 2326-5191

    eISSN： 2326-5205

  21. 下顎骨骨炎が先行して発症した高安動脈炎の1例

    小嶋 郁穂, 阪本 真弥, 飯久保 正弘, 白井 剛志, 大田 英揮, 常陸 真, 村田 隆紀, 明石 敏昭, 笹野 高嗣

    歯科放射線　57　(増刊)　57-57　2017年5月

    出版者・発行元： (NPO)日本歯科放射線学会

    ISSN： 0389-9705

    eISSN： 2185-6311

  22. Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface

    Tsuyoshi Shirai, Hiroshi Fujii, Tomoyuki Muto, Yuko Shirota, Yoko Fujita, Tomonori Ishii, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　68　2016年10月

    ISSN： 2326-5191

    eISSN： 2326-5205

  23. Bortezomib Treatment Induces Higher Mortality Rate in Lupus Model Mice with High Disease Activity

    Hiroshi Fujii, Tomoko Ikeda, Masato Nose, Tomoyuki Muto, Kanae Akita, Yukiko Kamogawa, Tsuyoshi Shirai, Yuko Shirota, Tomonori Ishii, Hideo Harigae

    ARTHRITIS & RHEUMATOLOGY　68　2016年10月

    ISSN： 2326-5191

    eISSN： 2326-5205

  24. 心室細動で発症し冠攣縮性狭心症と肺高血圧症を合併した好酸球性多発血管炎性肉芽腫症(EGPA)の1例

    紺野亮, 建部俊介, 杉村宏一郎, 青木竜男, 山本沙織, 矢尾板信裕, 佐藤遥, 神津克也, 羽尾清貴, 高橋潤, 中野誠, 福田浩二, 白井剛志, 杉浦久敏, 中嶋壮太, 石井智徳, 下川宏明

    日本循環器学会東北地方会(Web)　163rd　TOHOKU163,4 (WEB ONLY)　2016年

  25. Enhanced Oxidant Signaling in Inflammatory Macrophages in Rheumatoid Arthritis (RA) and in Coronary Artery Disease (CAD)

    Tsuyoshi Shirai, Benedikt Schaefgen, Barbara Wallis, Eric L. Matteson, Themistocles L. Assimes, David G. Harrison, Jorg Goronzy, Cornelia M. Weyand

    ARTHRITIS & RHEUMATOLOGY　67　2015年10月

    ISSN： 2326-5191

    eISSN： 2326-5205

  26. Distinct Profiles of Proinflammatory Macrophages in Rheumatoid Arthritis and Coronary Artery Disease.

    Tsuyoshi Shirai, Eric L. Matteson, David G. Harrison, Barbara B. Wallis, Themistocles L. Assimes, Jorg J. Goronzy, Cornelia M. Weyand

    ARTHRITIS & RHEUMATOLOGY　66　S187-S187　2014年10月

    ISSN： 2326-5191

    eISSN： 2326-5205

  27. FATE OF COLLAGEN DISEASE RELATED DIGITAL SKIN ULCERS TREATED ONLY UNDER CURRENTLY APPROVED THERAPIES: A CONTROL STUDY COMPARING WITH THE NEW SHOCKWAVE THERAPY TOWARD DIGITAL ULCERS OF SCLERODERMA

    S. Saito, Y. Kamogawa, K. Nakamura, R. Watanabe, Y. Fujita, T. Shirai, Y. Shirota, H. Fuji, T. Ishii, K. Ito, H. Shimokawa, H. Takemori, T. Konta, A. Komatsuda, T. Izumiyama, Y. Hirabayashi, Y. Sato, Y. Urata, Y. Kawaguchi, H. Harigae

    ANNALS OF THE RHEUMATIC DISEASES　73　568-569　2014年6月

    DOI： 10.1136/annrheumdis-2014-eular.3064 　

    ISSN： 0003-4967

    eISSN： 1468-2060

  28. 9. 多剤併用療法に抵抗性のループス腎炎に免疫吸着法(Immunoadsorption Plasmapheresis)を施行した2例(一般演題,日本アフェレシス学会第23回東北アフェレーシス研究会抄録)

    鈴木 舞, 鴨川 由起子, 中村 恭平, 渡部 龍, 白井 剛志, 藤田 洋子, 城田 祐子, 藤井 博司, 齋藤 真一郎, 石井 智徳, 張替 秀郎

    日本アフェレシス学会雑誌　32　(3)　241-241　2013年

    出版者・発行元： 日本アフェレシス学会

    ISSN： 1340-5888

  29. A Novel Method for Quantitative and Functional Analysis of Autophagy Using Flow Cytometry in Activated Human Primary T Cells

    Ryu Watanabe, Hiroshi Fujii, Yukiko Kamogawa, Kyohei Nakamura, Tsuyoshi Shirai, Yumi Tajima, Shinichiro Saito, Tomonori Ishii, Hideo Harigae

    ARTHRITIS AND RHEUMATISM　64　(10)　S982-S983　2012年10月

    ISSN： 0004-3591

  30. Retroviral Vector System Identified FLRT2 As a Novel Cell Surface Autoantigen Against Anti-Endothelial Cell Antibodies in Systemic Lupus Erythematosus.

    Tsuyoshi Shirai, Hiroshi Fujii, Masao Ono, Kyohei Nakamura, Ryu Watanabe, Yumi Sasaki, Naruhiko Takasawa, Tomonori Ishii, Hideo Harigae

    ARTHRITIS AND RHEUMATISM　63　(10)　S560-S561　2011年10月

    ISSN： 0004-3591

  31. シェーグレン症候群 原発性シェーグレン症候群に合併した肺動脈性肺高血圧症(PAH)に対する免疫抑制療法 (日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集)

    中村恭平, 石井智徳, 田島結実, 白井剛志, 渡部龍, 藤井博司, 高澤徳彦, 張替秀郎

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　55回・20回　450-450　2011年6月

  32. SLE SLEにおけるHBs抗体及びHBc抗体の保有率と免疫抑制療法の安全性 (日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集)

    渡部龍, 中村恭平, 白井剛志, 田島結実, 藤井博司, 高澤徳彦, 石井智徳, 張替秀郎

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　55回・20回　446-446　2011年6月

  33. SLE SLE患者リンパ球におけるアンギオテンシンIIの作用解析 (日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集)

    田島結実, 中村恭平, 渡部龍, 白井剛志, 藤井博司, 高澤徳彦, 石井智徳, 張替秀郎

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　55回・20回　341-341　2011年6月

  34. 自己抗体 レトロウイルスベクターシステムを用いた抗血管内皮細胞抗体対応自己抗原FLRT2の同定 (日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集)

    白井剛志, 藤井博司, 中村恭平, 渡部龍, 田島結実, 高澤徳彦, 石井智徳, 張替秀郎

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　55回・20回　320-320　2011年6月

  35. 当科におけるChurg‐Strauss症候群12例の臨床病理学的検討

    渡部龍, 白井剛志, 田島結実, 藤井博司, 高澤徳彦, 石井智徳, 張替秀郎, 鈴木直輝, 竪山真規, 糸山泰人

    臨床リウマチ　23　(1)　62-67　2011年3月30日

    出版者・発行元： 一般社団法人 日本臨床リウマチ学会

    DOI： 10.14961/cra.23.62 　

    ISSN： 0914-8760

    詳細を見る 詳細を閉じる

    目的：Churg-Strauss症候群（CSS）に伴う臓器障害は多彩で，皮膚や神経だけでなく，ときに心臓，肺，腎臓，消化管なども障害される．また，病理組織においては，好酸球浸潤を伴う壊死性血管炎や血管外肉芽腫の存在が特徴的とされている．そこで，当科で経験したCSS12例の臓器障害を含めた臨床的特徴と，得られた病理所見について検討した．<br>対象・方法：当科外来通院歴のあるCSS12例を対象とし，臨床病理学特徴を後方視的に検討した．<br>結果：<br>①患者背景<br>男性５例，女性７例，平均発症年齢は51.8歳，ANCA陽性は７例（58％）であった．<br>②臓器障害<br>全例で気管支喘息と多発単神経炎を認め，皮膚病変９例（75％），副鼻腔炎８例（67％），心病変５例（41％），肺病変５例（41％），感覚器病変４例（33％），中枢神経病変２例（17％），消化器病変と腎病変は１例ずつ（8.3％）であった．ANCAの陽性例で皮膚病変が有意に多く，陰性例で心病変と肺病変が多い傾向を認めた．<br>③病理学的検討<br>皮膚生検（６例）では全例で好酸球浸潤を認めたが，壊死性血管炎と血管外肉芽腫は１例ずつであった．また，神経生検（４例）では，血管炎や血管外肉芽腫の所見はみられなかった．<br>結論：当科におけるCSS12例の検討でも多彩な臓器障害がみられ，ANCA陽性例では皮膚病変が多かった．しかし，特徴的とされる病理像が得られた症例は稀であった．

  36. 当科におけるChurg‐Strauss症候群12例の臨床病理学的検討

    渡部龍, 白井剛志, 田島結実, 藤井博司, 高澤徳彦, 鈴木直輝, 竪山真規, 糸山泰人, 石井智徳, 張替秀郎

    末梢神経　21　(2)　247-248　2010年12月1日

    ISSN： 0917-6772

  37. 血管炎・APS 当科膠原病診療におけるPR3-ANCA陽性患者の検討 (日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集)

    白井剛志, 渡部龍, 田島結実, 藤井博司, 高澤徳彦, 石井智徳, 張替秀郎

    日本リウマチ学会総会・学術集会・国際リウマチシンポジウムプログラム・抄録集　54回・19回　544-544　2010年3月

  38. 当科におけるChurg‐Strauss症候群12例の臨床病理学的検討

    渡部龍, 白井剛志, 田島結実, 藤井博司, 高澤徳彦, 鈴木直輝, 竪山真規, 糸山泰人, 石井智徳, 張替秀郎

    日本末梢神経学会学術集会プログラム・抄録　21st　48　2010年

︎全件表示 ︎最初の5件までを表示

講演・口頭発表等 20

  1. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis

    Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori Ishii, Yuko Shirota, Fumiyoshi Fujishima, Fumiaki Takahashi, Yoichi Kakuta, Yoshitake Kanazawa, Atsushi Masamune, Yoshikatsu Saiki, Hideo Harigae, Hiroshi Fujii

    Nature Communications　2020年12月

  2. Serum and genetic biomarkers of Takayasu arteritis–which are truly useful? 招待有り

    Tsuyoshi Shirai

    26th Asia-Pacific League of Associations for Rheumatology Congress　2024年8月24日

  3. Novel Autoantibodies in Takayasu Arteritis Suggest Gut-vessel Connection in Vascular Inflammation 招待有り

    Tsuyoshi Shirai

    The 88th Annual Scientific Meeting of the Japanese Circulation Society　2024年3月9日

  4. 自己抗体から紐解く疾患の病理形態 招待有り

    白井 剛志

    第112回日本病理学会総会　2023年4月14日

  5. Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis 国際会議

    Tomoyuki Mutoh, Tsuyoshi Shirai, Tomonori Ishii, Yuko Shirota, Hideo Harigae, Hiroshi Fujii

    American College of Rheumatology Annual Meeting 2019　2019年11月14日

  6. 著明な倦怠感を認め、血小板低下を来した一例

    佐藤紘子, 永井泰地, 武藤智之, 町山智章, 鴨川由起子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

    第18回東北臨床免疫研究会　2019年8月24日

  7. 膠原病関連肺動脈性高血圧症における各種自己抗体別にみた長期予後の違いについての検討

    城田祐子, 白井剛志, 藤井博司, 小寺隆雄, 亀岡淳一, 石井智徳, 張替秀郎

    第63回日本リウマチ学会総会・学術集会 ワークショップ　2019年4月16日

  8. 血管ベーチェット病の臨床的特徴と治療内容の検討

    佐藤紘子, 星陽介, 町山智章, 鴨川由起子, 藤田洋子, 白井剛志, 藤井博司, 石井智徳, 張替秀郎

    佐藤紘子、星陽介、町山智章、鴨川由起子、藤田洋子、白井剛志、藤井博司、石井智徳、張替秀郎　2019年4月16日

  9. 生物学的製剤を使用した大型血管炎患者の検討

    白井剛志, 武藤智之, 藤田洋子, 藤井博司, 石井智徳, 平林泰彦, 張替秀郎

    第63回日本リウマチ学会総会・学術集会 ワークショップ　2019年4月16日

  10. Identification of endothelial protein C receptor and scavenger receptor class B type 1 as major autoantigens in Takayasu arteritis 国際会議

    Shirai T, Mutoh T, Fujii H, Ishii T, Harigae H

    EULAR 2019　2019年

  11. Insufficient Use of Corticosteroids Results in Higher Relapse in Takayasu Arteritis 国際会議

    Tomoyuki Muto, Tsuyoshi Shirai, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    American College of Rheumatology Annual Meeting 2018　2018年10月23日

  12. High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis 国際会議

    Tsuyoshi Shirai, Tomoyuki Muto, Yuko Shirota, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae

    American College of Rheumatology Annual Meeting 2018　2018年10月23日

  13. 眼窩内腫瘤による視力及び眼球運動障害を呈した難治性多発血管炎性肉芽腫症(GPA)の一例

    桑田 亮, 城田 祐子, 石井 悠翔, 星 陽介, 藤田 洋子, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　2018年3月

  14. ベーチェット病における抗TNF製剤の有効性の検討

    佐藤 紘子, 星 陽介, 藤田 洋子, 白井 剛志, 城田 祐子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　2018年3月

  15. 高安動脈炎における再燃率とリスク因子の検討

    武藤 智之, 白井 剛志, 藤田 洋子, 城田 祐子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　2018年3月

  16. リウマチ性疾患の合併症(感染症以外・アミロイドーシス・その他)3:その他2 膠原病性肺動脈性肺高血圧症(CTD-PAH)における予後予測因子と死因について

    城田 祐子, 星 陽介, 佐藤 紘子, 藤田 洋子, 白井 剛志, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　2018年3月

  17. 強皮症・MCTD・重複症候群1 全身性強皮症に伴う難治性皮膚潰瘍に対する低出力衝撃波療法の有効性・安全性検証試験

    石井 智徳, 川口 鎮司, 石川 治, 竹森 弘光, 高澤 徳彦, 小林 仁, 安岡 秀剛, 高橋 裕一, 小寺 隆雄, 高井 修, 中屋 来哉, 泉山 朋政, 齋藤 真一郎, 鴨川 由起子, 藤田 洋子, 白井 剛志, 城田 祐子, 藤井 博司, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　2018年3月

  18. 血管炎2:大型血管炎の臨床研究 大型血管炎における合併症・併存症の検討

    白井 剛志, 武藤 智之, 城田 祐子, 藤井 博司, 石井 智徳, 張替 秀郎

    日本リウマチ学会総会・学術集会プログラム・抄録集　2018年3月

  19. Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries 国際会議

    Tsuyoshi Shirai, Hiroshi Fujii, Yoko Fujita, Yuko Shirota, Tomonori Ishii, Hideo Harigae

    American College of Rheumatology Annual Meeting 2017　2017年11月7日

  20. Establishment of a Powerful Method to Identify Autoantigens Expressed on the Cell Surface 国際会議

    Tsuyoshi Shirai, Hiroshi Fujii, Tomoyuki Muto, Yuko Shirota, Yoko Fujita, Tomonori Ishii, Hideo Harigae

    American College of Rheumatology Annual Meeting 2016　2016年11月13日

︎全件表示 ︎最初の5件までを表示

産業財産権 2

  1. 炎症性腸疾患の診断方法、診断プローブ及び診断キット

    白井剛志, 藤井博司, 石井智徳, 張替秀郎ら

    産業財産権の種類: 特許権

  2. 高安動脈炎の診断方法、診断マーカー及び診断キット

    白井剛志, 藤井博司, 石井智徳, 張替秀郎

    産業財産権の種類: 特許権

共同研究・競争的資金等の研究課題 6

  1. 高安動脈炎と潰瘍性大腸炎に共通する抗EPCR抗体を軸とした病態解明と臨床応用の検討

    白井 剛志

    2024年4月1日 ～ 2027年3月31日

  2. 共通病態を基盤とした高安動脈炎と潰瘍性大腸炎を包括する新規症候群の検討

    白井 剛志

    2021年4月1日 ～ 2024年3月31日

    詳細を見る 詳細を閉じる

    高安動脈炎における腸内細菌叢異常の解析として、腸内細菌叢の次世代シークエンサーを用いたメタゲノム解析を行った。高安動脈炎患者からの糞便を検体とし、糞便よりDNAを抽出し精製、次世代シークエンサーを用いて、16S rDNA V3・4領域のシークエンスを行った。20検体を用いて、シークエンス解析を行い、Ribosomal database project (RDP)による帰属分類群の推定を行った。この結果を用いて、高安動脈炎における腸内細菌叢の解析を進めている。臨床検体との比較では、腸内細菌叢異常を伴う症例では、bacterial translocationが考慮される、血流感染を起こしやすい可能性が考慮された。 抗EPCR抗体の臨床的意義の解析のために、消化管疾患を対象とし、潰瘍性大腸炎、Crohn病をはじめとする炎症性腸疾患や大腸がんを含む非炎症性疾患での抗体価測定を行った。抗EPCR抗体は潰瘍性大腸炎の70%以上で認められ、Crohn病では大腸炎を呈する症例に認められれたが、他の非炎症性疾患では出現せず、大腸炎に関連する事が明らかになった。また、疾患活動性との相関も一部で認められている。 自己抗体の向炎症能解析として、抗EPCR/SR-BI抗体を血管内皮細胞と共培養することにより、血管内皮細胞機能への影響、直接的な細胞傷害性、アポトーシス誘導、免疫担当細胞への機能修飾を検討した。内皮細胞機能への影響として、血管内皮細胞に抗EPCR/SR-BI抗体を添加し、接着分子や前炎症性サイトカインを定量した。EPCRによる炎症抑制作用は様々な細胞においてみとめられ、組織特異的な現象について検討している。

  3. 抗ＣＣＰ抗体産生Ｂ細胞レパトア解析による新規関節リウマチモニタリング方法の開発

    石井 智徳, 小笠原 康悦, 白井 剛志, 藤井 博司, 城田 祐子

    提供機関：Japan Society for the Promotion of Science

    制度名：Grants-in-Aid for Scientific Research

    研究種目：Grant-in-Aid for Scientific Research (C)

    研究機関：Tohoku University

    2017年4月1日 ～ 2020年3月31日

    詳細を見る 詳細を閉じる

    既存治療を行ったにもかかわらず活動性が消失しなかった関節リウマチ患者15名に対してアバタセプトによる治療を行った。治療前に、患者より採血を行い、末梢血よりリンパ球分離を行った。得られたリンパ球よりB細胞レセプターおよびT細胞レセプターのレパトア解析を行った。これらの患者に対して、アバタセプトによる治療を3か月以上行った。治療後、2度目のB細胞、およびT細胞のレパトア解析を行い、治療前のレパトアと比較した。アバタセプトによる治療は70％の患者で有効性を認めた。これら治療により効果を認めた患者から得られたリンパ球において、治療前後で特定のT細胞レパトアの減少を認めた.

  4. 解糖系酵素ピルビン酸キナーゼM2による炎症性疾患の制御 競争的資金

    白井 剛志

    2018年 ～ 2020年

  5. 新規自己抗体による高安動脈炎の病態解明と臨床応用 競争的資金

    白井 剛志

    2016年 ～ 2017年

  6. 脳症を呈する膠原病患者における抗EphB2抗体の臨床的・病原的意義の解明 競争的資金

    白井 剛志

    2013年 ～ 2015年

︎全件表示 ︎最初の5件までを表示